An observational study in Acute Otitis Media and Mastoiditis, sponsored by Pfizer. Completed at 8 sites in United States. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2023-05-23.
Sponsored by Pfizer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Otitis Media with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Otitis Media · United States.
Among the 110 studies in Otitis Media with a site in United States, this one is the 8th largest by enrollment of the 23 observational ones that give a count, is one of 8 that started in 2010, is one of 23 observational ones, and was the 37th registered.
241 studies on the registry are indexed under Otitis Media; 32 are open to participants now.
Browse Otitis Media studies →12 of the 110 studies in Otitis Media with a site in United States are open now. Recruiting first, the newest first:
Nader Shaikh · Sites in United States
Ages 6 mo–36 mo
ClinQure, Inc. · Sites in United States
Ages 6 mo+
Stanford University · Sites in United States
Ages 1–17
Timothy Shope · Sites in United States
Ages 6 mo–24 mo
Medentum Innovations · Sites in United States
Ages 3–17 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Otitis Media studies recruiting now, 5 (25%) set no upper age limit and 15 (75%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.
This study: 0 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 15 · Phase 3 21 · Phase 4 9
First in 1997; this study’s year is marked. 8 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 391 is above the median of 150 across 57 observational studies indexed under Otitis Media.
Median enrollment 119 across the 85 interventional studies, 200 across the 23 observational. Of the 84 that completed or were terminated, 42 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 110 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 8 studies filed under Otitis Media — fewer than ten, so there is no comparison to draw.
8 of the studies in Otitis Media with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06876259Timothy ShopeArtificial Intelligence Diagnostic Decision Support to Reduce Antimicrobial Prescriptions in Young Children With Colds | 2027-03-30 |
| NCT07328555Boston Children's HospitalDigital Otoscopy Versus Standard Otoscopy on the Diagnosis and Treatment of Otitis Media in Young Children | 2027-03-31 |
| NCT05608993Intermountain Health Care, Inc.RELAX: Reducing Length of Antibiotics for Children With Ear Infections | 2027-04 |
| NCT05353569Medical College of WisconsinCoherent Optical Detection of Middle Ear Disease | 2027-04 |
| NCT06944795Stanford UniversitySWIR Otoscopy Study | 2027-04-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 110 studies in Otitis Media with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prevnar (7 valent pneumococcal conjugate vaccine [7vPnC]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar. It is expected that the effectiveness of Prevnar 13 against ear infections in children will be similar to that observed following Prevnar. Pfizer has committed to conduct a postmarketing study of the impact of Prevnar 13 in reducing ear infections among children.
Children aged 6 weeks to 18 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Otitis media cases
Other: No intervention
Non interventional
Percentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 1
The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 1 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were computed along with exact 2-sided 95 percent (%) confidence interval (CI) based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this outcome measure (OM).
Time frame: Surveillance Year 1
Percentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 2
The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 2 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 2
Percentage of Streptococcus Pneumoniae Serotype Isolates From Middle Ear Fluid (MEF) Sample at Surveillance Year 3
The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 3 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 3
Percentage of Streptococcus Pneumoniae Serotype Isolates From Mastoiditis Sample at Surveillance Year 1
The distribution of S pneumoniae serotypes isolated from mastoiditis samples from children in the target population for vaccination over the surveillance year 1 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (1, 3, 7F, 14, 19A, 19F) and not included in Prevnar 13 (6C, 12, 15A, 15B, 15F, 21, 22F, 23A, 33F, 35B, 38) along with total (both included and not included in Prevnar 13 ), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1
Percentage of Streptococcus Pneumoniae Serotype Isolates From Mastoiditis Sample at Surveillance Year 2
The distribution of S pneumoniae serotypes isolated from mastoiditis samples from children in the target population for vaccination over the surveillance year 2 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (1, 3, 7F, 14, 19A, 19F) and not included in Prevnar 13 (6C, 12, 15A, 15B, 15F, 21, 22F, 23A, 33F, 35B, 38) along with total (both included and not included in Prevnar 13 ), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 2
Percentage of Streptococcus Pneumoniae Serotype Isolates From Mastoiditis Sample at Surveillance Year 3
The distribution of S pneumoniae serotypes isolated from mastoiditis samples from children in the target population for vaccination over the surveillance year 3 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (1, 3, 7F, 14, 19A, 19F) and not included in Prevnar 13 (6C, 12, 15A, 15B, 15F, 21, 22F, 23A, 33F, 35B, 38) along with total (both included and not included in Prevnar 13 ), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 3
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Amoxicillin: Middle Ear Fluid (MEF) Population
Antimicrobial susceptibility of S pneumoniae isolates for amoxicillin from MEF samples was categorized as resistant, susceptible or intermediate based on minimum inhibitory concentration (MIC) for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1, 2, 3
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Cefotaxime: Middle Ear Fluid (MEF) Population
Antimicrobial susceptibility of S pneumoniae isolates for cefotaxime from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1, 2, 3
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Ceftriaxone: Middle Ear Fluid (MEF) Population
Antimicrobial susceptibility of S pneumoniae isolates for ceftriaxone from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1, 2, 3
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Clindamycin: Middle Ear Fluid (MEF) Population
Antimicrobial susceptibility of S pneumoniae isolates for clindamycin from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1, 2, 3
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Erythromycin: Middle Ear Fluid (MEF) Population
Antimicrobial susceptibility of S pneumoniae isolates for erythromycin from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19A, 19F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1, 2, 3
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Penicillin: Middle Ear Fluid (MEF) Population
Antimicrobial susceptibility of S pneumoniae isolates for penicillin from MEF samples were summarized by providing the range of MICs for penicillin tested and the percentage of the susceptibility interpretation was categorized as resistant, susceptible or intermediate for each serotype, and for each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95 % CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1, 2, 3
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Trimethoprim/Sulfamethoxazole (TMP/S): Middle Ear Fluid (MEF) Population
Antimicrobial susceptibility of S pneumoniae isolates for TMP/S from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19A, 19F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1, 2, 3
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Ceftriaxone: Mastoid Population
Antimicrobial susceptibility of S pneumoniae isolates for ceftriaxone from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1, 2, 3
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Clindamycin: Mastoid Population
Antimicrobial susceptibility of S pneumoniae isolates for clindamycin from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1, 2, 3
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Erythromycin: Mastoid Population
Antimicrobial susceptibility of S pneumoniae isolates for erythromycin from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1, 2, 3
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Penicillin: Mastoid Population
Antimicrobial susceptibility of S pneumoniae isolates for penicillin from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1, 2, 3
Antimicrobial Susceptibility of Streptococcus Pneumoniae Isolates for Trimethoprim/Sulfamethoxazole (TMP/S): Mastoid Population
Antimicrobial susceptibility of S pneumoniae isolates for TMP/S from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
Time frame: Surveillance Year 1, 2, 3
Percentage of Participants With Primary Clinical Diagnosis of Otitis Media
Percentage of participants with primary diagnosis of otitis media was computed along with exact 2-sided 95% CI based on the observed proportion of participants for each of the 3 surveillance year. Results for baseline period were analyzed for participants who received routinely recommended vaccination of 13vPnC. The cases of otitis media reported during the baseline period were captured by the Texas Children's Hospital, which was the only site that collected this information during the baseline period. Percentage of participants was calculated by dividing number of participants with at least 1 MEF sample for the specified year by total number of participants with at least 1 MEF sample for the 3 year surveillance period.
Time frame: Baseline Year 1, 2, 3; Surveillance Year 1, 2, 3
Percentage of Participants With Primary Clinical Diagnosis of Mastoiditis
Percentage of participants with primary diagnosis of mastoiditis was computed along with exact 2-sided 95% CI based on the observed proportion of participants for each of the 3 surveillance year. Percentage of participants was calculated by dividing number of participants with at least 1 mastoid sample for the specified year by total number of participants with at least 1 mastoid sample for the 3 year surveillance period.
Time frame: Surveillance Year 1, 2, 3
| Milestone | MEF Population | Mastoid Population |
|---|---|---|
| Started | 357 | 34 |
| Completed | 357 | 34 |
| Not completed | 0 | 0 |
The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 1 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were computed along with exact 2-sided 95 percent (%) confidence interval (CI) based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this outcome measure (OM).
| percentage of isolates | MEF Population |
|---|---|
| Serotype included in Prevnar 13:3 | 5.9 (2.6 to 11.3) |
| Serotype included in Prevnar 13:7F | 0.7 (0.0 to 4.1) |
| Serotype included in Prevnar 13:19A | 31.9 (24.1 to 40.4) |
| Serotype included in Prevnar 13:19F | 2.2 (0.5 to 6.4) |
| Total Serotype included in Prevnar 13 | 40.7 (32.4 to 49.5) |
| Serotype not included in Prevnar 13:6C | 6.7 (3.1 to 12.3) |
| Serotype not included in Prevnar 13:7C | 1.5 (0.2 to 5.2) |
| Serotype not included in Prevnar 13:9N | 2.2 (0.5 to 6.4) |
| Serotype not included in Prevnar 13:10 | 3.7 (1.2 to 8.4) |
| Serotype not included in Prevnar 13:11 | 3.7 (1.2 to 8.4) |
| Serotype not included in Prevnar 13:12 | 0.7 (0.0 to 4.1) |
| Serotype not included in Prevnar 13:12F | 0.0 (0.0 to 2.7) |
| Serotype not included in Prevnar 13:13 | 0.7 (0.0 to 4.1) |
| Serotype not included in Prevnar 13:15A | 3.7 (1.2 to 8.4) |
| Serotype not included in Prevnar 13:15B | 4.4 (1.6 to 9.4) |
| Serotype not included in Prevnar 13:15C | 3.7 (1.2 to 8.4) |
| Serotype not included in Prevnar 13:15F | 0.0 (0.0 to 2.7) |
| Serotype not included in Prevnar 13:16 | 1.5 (0.2 to 5.2) |
| Serotype not included in Prevnar 13:17 | 0.0 (0.0 to 2.7) |
| Serotype not included in Prevnar 13:20 | 0.0 (0.0 to 2.7) |
| Serotype not included in Prevnar 13:21 | 3.0 (0.8 to 7.4) |
| Serotype not included in Prevnar 13:22F | 1.5 (0.2 to 5.2) |
| Serotype not included in Prevnar 13:23A | 3.7 (1.2 to 8.4) |
| Serotype not included in Prevnar 13:23B | 2.2 (0.5 to 6.4) |
| Serotype not included in Prevnar 13:31 | 2.2 (0.5 to 6.4) |
| Serotype not included in Prevnar 13:33A | 0.7 (0.0 to 4.1) |
| Serotype not included in Prevnar 13:33F | 3.0 (0.8 to 7.4) |
| Serotype not included in Prevnar 13:34 | 0.0 (0.0 to 2.7) |
| Serotype not included in Prevnar 13:35B | 6.7 (3.1 to 12.3) |
| Serotype not included in Prevnar 13:35F | 0.0 (0.0 to 2.7) |
| Serotype not included in Prevnar 13:38 | 0.7 (0.0 to 4.1) |
| Total Serotype not included in Prevnar 13 | 56.3 (47.5 to 64.8) |
| Serotype clumps | 1.5 (0.2 to 5.2) |
| Serotype Missing/non-viable | 1.5 (0.2 to 5.2) |
The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 2 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | MEF Population |
|---|---|
| Serotype included in Prevnar 13:3 | 6.3 (2.6 to 12.6) |
| Serotype included in Prevnar 13:7F | 0.0 (0.0 to 3.3) |
| Serotype included in Prevnar 13:19A | 23.4 (15.9 to 32.4) |
| Serotype included in Prevnar 13:19F | 1.8 (0.2 to 6.4) |
| Total Serotype included in Prevnar 13 | 31.5 (23.0 to 41.0) |
| Serotype not included in Prevnar 13:6C | 4.5 (1.5 to 10.2) |
| Serotype not included in Prevnar 13:7C | 0.9 (0.0 to 4.9) |
| Serotype not included in Prevnar 13:9N | 0.0 (0.0 to 3.3) |
| Serotype not included in Prevnar 13:10 | 0.9 (0.0 to 4.9) |
| Serotype not included in Prevnar 13:11 | 7.2 (3.2 to 13.7) |
| Serotype not included in Prevnar 13:12 | 0.0 (0.0 to 3.3) |
| Serotype not included in Prevnar 13:12F | 0.9 (0.0 to 4.9) |
| Serotype not included in Prevnar 13:13 | 0.0 (0.0 to 3.3) |
| Serotype not included in Prevnar 13:15A | 0.9 (0.0 to 4.9) |
| Serotype not included in Prevnar 13:15B | 4.5 (1.5 to 10.2) |
| Serotype not included in Prevnar 13:15C | 2.7 (0.6 to 7.7) |
| Serotype not included in Prevnar 13:15F | 0.0 (0.0 to 3.3) |
| Serotype not included in Prevnar 13:16 | 2.7 (0.6 to 7.7) |
| Serotype not included in Prevnar 13:17 | 1.8 (0.2 to 6.4) |
| Serotype not included in Prevnar 13:20 | 0.0 (0.0 to 3.3) |
| Serotype not included in Prevnar 13:21 | 9.0 (4.4 to 15.9) |
| Serotype not included in Prevnar 13:22F | 0.9 (0.0 to 4.9) |
| Serotype not included in Prevnar 13:23A | 4.5 (1.5 to 10.2) |
| Serotype not included in Prevnar 13:23B | 7.2 (3.2 to 13.7) |
| Serotype not included in Prevnar 13:31 | 1.8 (0.2 to 6.4) |
| Serotype not included in Prevnar 13:33A | 0.0 (0.0 to 3.3) |
| Serotype not included in Prevnar 13:33F | 0.0 (0.0 to 3.3) |
| Serotype not included in Prevnar 13:34 | 0.9 (0.0 to 4.9) |
| Serotype not included in Prevnar 13:35B | 13.5 (7.8 to 21.3) |
| Serotype not included in Prevnar 13:35F | 0.9 (0.0 to 4.9) |
| Serotype not included in Prevnar 13:38 | 0.9 (0.0 to 4.9) |
| Total Serotype not included in Prevnar 13 | 66.7 (57.1 to 75.3) |
| Serotype clumps | 0.9 (0.0 to 4.9) |
| Serotype Missing/non-viable | 0.9 (0.0 to 4.9) |
The distribution of S pneumoniae serotypes isolated from MEF samples from children in the target population for vaccination over the surveillance year 3 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (3, 7F, 19A, 19F) and not included in Prevnar 13 (6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38) along with total (both included and not included), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | MEF Population |
|---|---|
| Serotype included in Prevnar 13:3 | 7.2 (3.2 to 13.7) |
| Serotype included in Prevnar 13:7F | 0.0 (0.0 to 3.3) |
| Serotype included in Prevnar 13:19A | 9.9 (5.1 to 17.0) |
| Serotype included in Prevnar 13:19F | 6.3 (2.6 to 12.6) |
| Total Serotype included in Prevnar 13 | 23.4 (15.9 to 32.4) |
| Serotype not included in Prevnar 13:6C | 1.8 (0.2 to 6.4) |
| Serotype not included in Prevnar 13:7C | 0.0 (0.0 to 3.3) |
| Serotype not included in Prevnar 13:9N | 0.9 (0.0 to 4.9) |
| Serotype not included in Prevnar 13:10 | 2.7 (0.6 to 7.7) |
| Serotype not included in Prevnar 13:11 | 3.6 (1.0 to 9.0) |
| Serotype not included in Prevnar 13:12 | 0.0 (0.0 to 3.3) |
| Serotype not included in Prevnar 13:12F | 0.0 (0.0 to 3.3) |
| Serotype not included in Prevnar 13:13 | 0.0 (0.0 to 3.3) |
| Serotype not included in Prevnar 13:15A | 6.3 (2.6 to 12.6) |
| Serotype not included in Prevnar 13:15B | 5.4 (2.0 to 11.4) |
| Serotype not included in Prevnar 13:15C | 5.4 (2.0 to 11.4) |
| Serotype not included in Prevnar 13:15F | 0.9 (0.0 to 4.9) |
| Serotype not included in Prevnar 13:16 | 5.4 (2.0 to 11.4) |
| Serotype not included in Prevnar 13:17 | 0.9 (0.0 to 4.9) |
| Serotype not included in Prevnar 13:20 | 0.9 (0.0 to 4.9) |
| Serotype not included in Prevnar 13:21 | 5.4 (2.0 to 11.4) |
| Serotype not included in Prevnar 13:22F | 2.7 (0.6 to 7.7) |
| Serotype not included in Prevnar 13:23A | 2.7 (0.6 to 7.7) |
| Serotype not included in Prevnar 13:23B | 8.1 (3.8 to 14.8) |
| Serotype not included in Prevnar 13:31 | 4.5 (1.5 to 10.2) |
| Serotype not included in Prevnar 13:33A | 0.0 (0.0 to 3.3) |
| Serotype not included in Prevnar 13:33F | 1.8 (0.2 to 6.4) |
| Serotype not included in Prevnar 13:34 | 0.9 (0.0 to 4.9) |
| Serotype not included in Prevnar 13:35B | 10.8 (5.7 to 18.1) |
| Serotype not included in Prevnar 13:35F | 1.8 (0.2 to 6.4) |
| Serotype not included in Prevnar 13:38 | 1.8 (0.2 to 6.4) |
| Total Serotype not included in Prevnar 13 | 74.8 (65.6 to 82.5) |
| Serotype clumps | 0.0 (0.0 to 3.3) |
| Serotype Missing/non-viable | 1.8 (0.2 to 6.4) |
The distribution of S pneumoniae serotypes isolated from mastoiditis samples from children in the target population for vaccination over the surveillance year 1 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (1, 3, 7F, 14, 19A, 19F) and not included in Prevnar 13 (6C, 12, 15A, 15B, 15F, 21, 22F, 23A, 33F, 35B, 38) along with total (both included and not included in Prevnar 13 ), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | Mastoid Population |
|---|---|
| Serotype included in Prevnar 13:1 | 0.0 (0.0 to 18.5) |
| Serotype included in Prevnar 13:3 | 0.0 (0.0 to 18.5) |
| Serotype included in Prevnar 13:7F | 0.0 (0.0 to 18.5) |
| Serotype included in Prevnar 13:14 | 0.0 (0.0 to 18.5) |
| Serotype included in Prevnar 13:19A | 38.9 (17.3 to 64.3) |
| Serotype included in Prevnar 13:19F | 11.1 (1.4 to 34.7) |
| Total Serotype included in Prevnar 13 | 50.0 (26.0 to 74.0) |
| Serotype not included in Prevnar 13:6C | 5.6 (0.1 to 27.3) |
| Serotype not included in Prevnar 13:12 | 5.6 (0.1 to 27.3) |
| Serotype not included in Prevnar 13:15A | 5.6 (0.1 to 27.3) |
| Serotype not included in Prevnar 13:15B | 5.6 (0.1 to 27.3) |
| Serotype not included in Prevnar 13:15F | 0.0 (0.0 to 18.5) |
| Serotype not included in Prevnar 13:21 | 0.0 (0.0 to 18.5) |
| Serotype not included in Prevnar 13:22F | 11.1 (1.4 to 34.7) |
| Serotype not included in Prevnar 13:23A | 5.6 (0.1 to 27.3) |
| Serotype not included in Prevnar 13:33F | 0.0 (0.0 to 18.5) |
| Serotype not included in Prevnar 13:35B | 5.6 (0.1 to 27.3) |
| Serotype not included in Prevnar 13:38 | 5.6 (0.1 to 27.3) |
| Total Serotype not included in Prevnar 13 | 50.0 (26.0 to 74.0) |
| Serotype missing/non-viable | 0.0 (0.0 to 18.5) |
The distribution of S pneumoniae serotypes isolated from mastoiditis samples from children in the target population for vaccination over the surveillance year 2 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (1, 3, 7F, 14, 19A, 19F) and not included in Prevnar 13 (6C, 12, 15A, 15B, 15F, 21, 22F, 23A, 33F, 35B, 38) along with total (both included and not included in Prevnar 13 ), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | Mastoid Population |
|---|---|
| Serotype included in Prevnar 13:1 | 0.0 (0.0 to 41.0) |
| Serotype included in Prevnar 13:3 | 28.6 (3.7 to 71.0) |
| Serotype included in Prevnar 13:7F | 0.0 (0.0 to 41.0) |
| Serotype included in Prevnar 13:14 | 0.0 (0.0 to 41.0) |
| Serotype included in Prevnar 13:19A | 71.4 (29.0 to 96.3) |
| Serotype included in Prevnar 13:19F | 0.0 (0.0 to 41.0) |
| Total Serotype included in Prevnar 13 | 100.0 (59.0 to 100.0) |
| Serotype not included in Prevnar 13:6C | 0.0 (0.0 to 41.0) |
| Serotype not included in Prevnar 13:12 | 0.0 (0.0 to 41.0) |
| Serotype not included in Prevnar 13:15A | 0.0 (0.0 to 41.0) |
| Serotype not included in Prevnar 13:15B | 0.0 (0.0 to 41.0) |
| Serotype not included in Prevnar 13:15F | 0.0 (0.0 to 41.0) |
| Serotype not included in Prevnar 13:21 | 0.0 (0.0 to 41.0) |
| Serotype not included in Prevnar 13:22F | 0.0 (0.0 to 41.0) |
| Serotype not included in Prevnar 13:23A | 0.0 (0.0 to 41.0) |
| Serotype not included in Prevnar 13:33F | 0.0 (0.0 to 41.0) |
| Serotype not included in Prevnar 13:35B | 0.0 (0.0 to 41.0) |
| Serotype not included in Prevnar 13:38 | 0.0 (0.0 to 41.0) |
| Total Serotype not included in Prevnar 13 | 0.0 (0.0 to 41.0) |
| Serotype missing/non-viable | 0.0 (0.0 to 41.0) |
The distribution of S pneumoniae serotypes isolated from mastoiditis samples from children in the target population for vaccination over the surveillance year 3 were presented. The percentage of isolates of S pneumoniae serotypes included in Prevnar 13 (1, 3, 7F, 14, 19A, 19F) and not included in Prevnar 13 (6C, 12, 15A, 15B, 15F, 21, 22F, 23A, 33F, 35B, 38) along with total (both included and not included in Prevnar 13 ), clumps and missing or non-viable were computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | Mastoid Population |
|---|---|
| Serotype included in Prevnar 13:1 | 0.0 (0.0 to 33.6) |
| Serotype included in Prevnar 13:3 | 44.4 (13.7 to 78.8) |
| Serotype included in Prevnar 13:7F | 0.0 (0.0 to 33.6) |
| Serotype included in Prevnar 13:14 | 0.0 (0.0 to 33.6) |
| Serotype included in Prevnar 13:19A | 11.1 (0.3 to 48.2) |
| Serotype included in Prevnar 13:19F | 11.1 (0.3 to 48.2) |
| Total Serotype included in Prevnar 13 | 66.7 (29.9 to 92.5) |
| Serotype not included in Prevnar 13:6C | 0.0 (0.0 to 33.6) |
| Serotype not included in Prevnar 13:12 | 0.0 (0.0 to 33.6) |
| Serotype not included in Prevnar 13:15A | 0.0 (0.0 to 33.6) |
| Serotype not included in Prevnar 13:15B | 0.0 (0.0 to 33.6) |
| Serotype not included in Prevnar 13:15F | 0.0 (0.0 to 33.6) |
| Serotype not included in Prevnar 13:21 | 0.0 (0.0 to 33.6) |
| Serotype not included in Prevnar 13:22F | 11.1 (0.3 to 48.2) |
| Serotype not included in Prevnar 13:23A | 0.0 (0.0 to 33.6) |
| Serotype not included in Prevnar 13:33F | 22.2 (2.8 to 60.0) |
| Serotype not included in Prevnar 13:35B | 0.0 (0.0 to 33.6) |
| Serotype not included in Prevnar 13:38 | 0.0 (0.0 to 33.6) |
| Total Serotype not included in Prevnar 13 | 33.3 (7.5 to 70.1) |
| Serotype missing/non-viable | 0.0 (0.0 to 33.6) |
Antimicrobial susceptibility of S pneumoniae isolates for amoxicillin from MEF samples was categorized as resistant, susceptible or intermediate based on minimum inhibitory concentration (MIC) for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | MEF Population |
|---|---|
| Serotype 3 at Year 1:S | 3.0 |
| Serotype 6C at Year 1:S | 3.0 |
| Serotype 7C at Year 1:S | 0.0 |
| Serotype 9N at Year 1:S | 0.7 |
| Serotype 10 at Year 1:S | 1.5 |
| Serotype 11 at Year 1:S | 1.5 |
| Serotype 12 at Year 1:S | 0.0 |
| Serotype 12F at Year 1:S | 0.0 |
| Serotype 13 at Year 1:S | 0.0 |
| Serotype 15A at Year 1:S | 1.5 |
| Serotype 15B at Year 1:S | 0.7 |
| Serotype 15C at Year 1:S | 3.0 |
| Serotype 15F at Year 1:S | 0.0 |
| Serotype 16 at Year 1:S | 0.0 |
| Serotype 17 at Year 1:S | 0.0 |
| Serotype 19A at Year 1:S | 3.0 |
| Serotype 19F at Year 1:S | 0.7 |
| Serotype 20 at Year 1:S | 0.0 |
| Serotype 21 at Year 1:S | 1.5 |
| Serotype 22F at Year 1:S | 0.0 |
| Serotype 23A at Year 1:S | 1.5 |
| Serotype 23B at Year 1:S | 0.7 |
| Serotype 31 at Year 1:S | 0.0 |
| Serotype 33A at Year 1:S | 0.7 |
| Serotype 33F at Year 1:S | 0.0 |
| Serotype 34 at Year 1:S | 0.0 |
| Serotype 35B at Year 1:S | 3.0 |
| Serotype 35F at Year 1:S | 0.0 |
| Serotype 38 at Year 1:S | 0.0 |
| Serotype clumps at Year 1:S | 0.0 |
| Serotype Missing/non-viable at Year 1:S | 0.0 |
| Serotype 3 at Year 2:S | 1.8 |
| Serotype 6C at Year 2:S | 0.9 |
| Serotype 7C at Year 2:S | 0.0 |
| Serotype 9N at Year 2:S | 0.0 |
| Serotype 10 at Year 2:S | 0.9 |
| Serotype 11 at Year 2:S | 2.7 |
| Serotype 12 at Year 2:S | 0.0 |
| Serotype 12F at Year 2:S | 0.9 |
| Serotype 13 at Year 2:S | 0.0 |
| Serotype 15A at Year 2:S | 0.9 |
| Serotype 15B at Year 2:S | 0.0 |
| Serotype 15C at Year 2:S | 2.7 |
| Serotype 15F at Year 2:S | 0.0 |
| Serotype 16 at Year 2:S | 0.9 |
| Serotype 17 at Year 2:S | 1.8 |
| Serotype 19A at Year 2:S | 1.8 |
| Serotype 19F at Year 2:S | 0.9 |
| Serotype 20 at Year 2:S | 0.0 |
| Serotype 21 at Year 2:S | 2.7 |
| Serotype 22F at Year 2:S | 0.0 |
| Serotype 23A at Year 2:S | 2.7 |
| Serotype 23B at Year 2:S | 2.7 |
| Serotype 31 at Year 2:S | 1.8 |
| Serotype 33A at Year 2:S | 0.0 |
| Serotype 33F at Year 2:S | 0.0 |
| Serotype 34 at Year 2:S | 0.9 |
| Serotype 35B at Year 2:S | 4.5 |
| Serotype 35F at Year 2:S | 0.9 |
| Serotype 38 at Year 2:S | 0.9 |
| Serotype clumps at Year 2:S | 0.0 |
| Serotype Missing/non-viable at Year 2:S | 0.9 |
| Serotype 3 at Year 3:S | 3.6 |
| Serotype 6C at Year 3:S | 0.0 |
| Serotype 7C at Year 3:S | 0.0 |
| Serotype 9N at Year 3:S | 0.9 |
| Serotype 10 at Year 3:S | 1.8 |
| Serotype 11 at Year 3:S | 1.8 |
| Serotype 12 at Year 3:S | 0.0 |
| Serotype 12F at Year 3:S | 0.0 |
| Serotype 13 at Year 3:S | 0.0 |
| Serotype 15A at Year 3:S | 2.7 |
| Serotype 15B at Year 3:S | 3.6 |
| Serotype 15C at Year 3:S | 0.9 |
| Serotype 15F at Year 3:S | 0.0 |
| Serotype 16 at Year 3:S | 3.6 |
| Serotype 17 at Year 3:S | 0.9 |
| Serotype 19A at Year 3:S | 0.0 |
| Serotype 19F at Year 3:S | 1.8 |
| Serotype 20 at Year 3:S | 0.9 |
| Serotype 21 at Year 3:S | 1.8 |
| Serotype 22F at Year 3:S | 0.0 |
| Serotype 23A at Year 3:S | 2.7 |
| Serotype 23B at Year 3:S | 6.3 |
| Serotype 31 at Year 3:S | 1.8 |
| Serotype 33A at Year 3:S | 0.0 |
| Serotype 33F at Year 3:S | 0.0 |
| Serotype 34 at Year 3:S | 0.0 |
| Serotype 35B at Year 3:S | 5.4 |
| Serotype 35F at Year 3:S | 0.0 |
| Serotype 38 at Year 3:S | 0.9 |
| Serotype clumps at Year 3:S | 0.0 |
| Serotype Missing/non-viable at Year 3:S | 0.0 |
| Serotype 3 at Year 1:I | 0.0 |
| Serotype 6C at Year 1:I | 0.0 |
| Serotype 7C at Year 1:I | 0.0 |
| Serotype 9N at Year 1:I | 0.0 |
| Serotype 10 at Year 1:I | 0.0 |
| Serotype 11 at Year 1:I | 0.0 |
| Serotype 12 at Year 1:I | 0.0 |
| Serotype 12F at Year 1:I | 0.0 |
| Serotype 13 at Year 1:I | 0.0 |
| Serotype 15A at Year 1:I | 0.0 |
| Serotype 15B at Year 1:I | 0.0 |
| Serotype 15C at Year 1:I | 0.0 |
| Serotype 15F at Year 1:I | 0.0 |
| Serotype 16 at Year 1:I | 0.0 |
| Serotype 17 at Year 1:I | 0.0 |
| Serotype 19A at Year 1:I | 5.9 |
| Serotype 19F at Year 1:I | 0.0 |
| Serotype 20 at Year 1:I | 0.0 |
| Serotype 21 at Year 1:I | 0.0 |
| Serotype 22F at Year 1:I | 0.0 |
| Serotype 23A at Year 1:I | 0.0 |
| Serotype 23B at Year 1:I | 0.0 |
| Serotype 31 at Year 1:I | 0.0 |
| Serotype 33A at Year 1:I | 0.0 |
| Serotype 33F at Year 1:I | 0.0 |
| Serotype 34 at Year 1:I | 0.0 |
| Serotype 35B at Year 1:I | 0.0 |
| Serotype 35F at Year 1:I | 0.0 |
| Serotype 38 at Year 1:I | 0.0 |
| Serotype clumps at Year 1:I | 0.0 |
| Serotype Missing/non-viable at Year 1:I | 0.0 |
| Serotype 3 at Year 2:I | 0.0 |
| Serotype 6C at Year 2:I | 0.0 |
| Serotype 7C at Year 2:I | 0.0 |
| Serotype 9N at Year 2:I | 0.0 |
| Serotype 10 at Year 2:I | 0.0 |
| Serotype 11 at Year 2:I | 0.0 |
| Serotype 12 at Year 2:I | 0.0 |
| Serotype 12F at Year 2:I | 0.0 |
| Serotype 13 at Year 2:I | 0.0 |
| Serotype 15A at Year 2:I | 0.0 |
| Serotype 15B at Year 2:I | 0.0 |
| Serotype 15C at Year 2:I | 0.0 |
| Serotype 15F at Year 2:I | 0.0 |
| Serotype 16 at Year 2:I | 0.0 |
| Serotype 17 at Year 2:I | 0.0 |
| Serotype 19A at Year 2:I | 0.0 |
| Serotype 19F at Year 2:I | 0.0 |
| Serotype 20 at Year 2:I | 0.0 |
| Serotype 21 at Year 2:I | 0.0 |
| Serotype 22F at Year 2:I | 0.0 |
| Serotype 23A at Year 2:I | 0.0 |
| Serotype 23B at Year 2:I | 0.0 |
| Serotype 31 at Year 2:I | 0.0 |
| Serotype 33A at Year 2:I | 0.0 |
| Serotype 33F at Year 2:I | 0.0 |
| Serotype 34 at Year 2:I | 0.0 |
| Serotype 35B at Year 2:I | 0.0 |
| Serotype 35F at Year 2:I | 0.0 |
| Serotype 38 at Year 2:I | 0.0 |
| Serotype clumps at Year 2:I | 0.0 |
| Serotype Missing/non-viable at Year 2:I | 0.0 |
| Serotype 3 at Year 3:I | 0.0 |
| Serotype 6C at Year 3:I | 0.0 |
| Serotype 7C at Year 3:I | 0.0 |
| Serotype 9N at Year 3:I | 0.0 |
| Serotype 10 at Year 3:I | 0.0 |
| Serotype 11 at Year 3:I | 0.0 |
| Serotype 12 at Year 3:I | 0.0 |
| Serotype 12F at Year 3:I | 0.0 |
| Serotype 13 at Year 3:I | 0.0 |
| Serotype 15A at Year 3:I | 0.0 |
| Serotype 15B at Year 3:I | 0.0 |
| Serotype 15C at Year 3:I | 0.0 |
| Serotype 15F at Year 3:I | 0.0 |
| Serotype 16 at Year 3:I | 0.0 |
| Serotype 17 at Year 3:I | 0.0 |
| Serotype 19A at Year 3:I | 2.7 |
| Serotype 19F at Year 3:I | 0.0 |
| Serotype 20 at Year 3:I | 0.0 |
| Serotype 21 at Year 3:I | 0.0 |
| Serotype 22F at Year 3:I | 0.0 |
| Serotype 23A at Year 3:I | 0.0 |
| Serotype 23B at Year 3:I | 0.0 |
| Serotype 31 at Year 3:I | 0.0 |
| Serotype 33A at Year 3:I | 0.0 |
| Serotype 33F at Year 3:I | 0.0 |
| Serotype 34 at Year 3:I | 0.0 |
| Serotype 35B at Year 3:I | 0.9 |
| Serotype 35F at Year 3:I | 0.0 |
| Serotype 38 at Year 3:I | 0.0 |
| Serotype clumps at Year 3:I | 0.0 |
| Serotype Missing/non-viable at Year 3:I | 0.0 |
| Serotype 3 at Year 1:R | 0.0 |
| Serotype 6C at Year 1:R | 0.0 |
| Serotype 7C at Year 1:R | 0.0 |
| Serotype 9N at Year 1:R | 0.0 |
| Serotype 10 at Year 1:R | 0.0 |
| Serotype 11 at Year 1:R | 0.0 |
| Serotype 12 at Year 1:R | 0.0 |
| Serotype 12F at Year 1:R | 0.0 |
| Serotype 13 at Year 1:R | 0.0 |
| Serotype 15A at Year 1:R | 0.0 |
| Serotype 15B at Year 1:R | 0.0 |
| Serotype 15C at Year 1:R | 0.0 |
| Serotype 15F at Year 1:R | 0.0 |
| Serotype 16 at Year 1:R | 0.0 |
| Serotype 17 at Year 1:R | 0.0 |
| Serotype 19A at Year 1:R | 0.0 |
| Serotype 19F at Year 1:R | 0.0 |
| Serotype 20 at Year 1:R | 0.0 |
| Serotype 21 at Year 1:R | 0.0 |
| Serotype 22F at Year 1:R | 0.0 |
| Serotype 23A at Year 1:R | 0.0 |
| Serotype 23B at Year 1:R | 0.0 |
| Serotype 31 at Year 1:R | 0.0 |
| Serotype 33A at Year 1:R | 0.0 |
| Serotype 33F at Year 1:R | 0.0 |
| Serotype 34 at Year 1:R | 0.0 |
| Serotype 35B at Year 1:R | 0.0 |
| Serotype 35F at Year 1:R | 0.0 |
| Serotype 38 at Year 1:R | 0.0 |
| Serotype clumps at Year 1:R | 0.0 |
| Serotype Missing/non-viable at Year 1:R | 0.0 |
| Serotype 3 at Year 2:R | 0.0 |
| Serotype 6C at Year 2:R | 0.0 |
| Serotype 7C at Year 2:R | 0.0 |
| Serotype 9N at Year 2:R | 0.0 |
| Serotype 10 at Year 2:R | 0.0 |
| Serotype 11 at Year 2:R | 0.0 |
| Serotype 12 at Year 2:R | 0.0 |
| Serotype 12F at Year 2:R | 0.0 |
| Serotype 13 at Year 2:R | 0.0 |
| Serotype 15A at Year 2:R | 0.0 |
| Serotype 15B at Year 2:R | 0.0 |
| Serotype 15C at Year 2:R | 0.0 |
| Serotype 15F at Year 2:R | 0.0 |
| Serotype 16 at Year 2:R | 0.0 |
| Serotype 17 at Year 2:R | 0.0 |
| Serotype 19A at Year 2:R | 1.8 |
| Serotype 19F at Year 2:R | 0.0 |
| Serotype 20 at Year 2:R | 0.0 |
| Serotype 21 at Year 2:R | 0.0 |
| Serotype 22F at Year 2:R | 0.0 |
| Serotype 23A at Year 2:R | 0.0 |
| Serotype 23B at Year 2:R | 0.0 |
| Serotype 31 at Year 2:R | 0.0 |
| Serotype 33A at Year 2:R | 0.0 |
| Serotype 33F at Year 2:R | 0.0 |
| Serotype 34 at Year 2:R | 0.0 |
| Serotype 35B at Year 2:R | 0.0 |
| Serotype 35F at Year 2:R | 0.0 |
| Serotype 38 at Year 2:R | 0.0 |
| Serotype clumps at Year 2:R | 0.0 |
| Serotype Missing/non-viable at Year 2:R | 0.0 |
| Serotype 3 at Year 3:R | 0.0 |
| Serotype 6C at Year 3:R | 0.0 |
| Serotype 7C at Year 3:R | 0.0 |
| Serotype 9N at Year 3:R | 0.0 |
| Serotype 10 at Year 3:R | 0.0 |
| Serotype 11 at Year 3:R | 0.0 |
| Serotype 12 at Year 3:R | 0.0 |
| Serotype 12F at Year 3:R | 0.0 |
| Serotype 13 at Year 3:R | 0.0 |
| Serotype 15A at Year 3:R | 0.0 |
| Serotype 15B at Year 3:R | 0.0 |
| Serotype 15C at Year 3:R | 0.0 |
| Serotype 15F at Year 3:R | 0.0 |
| Serotype 16 at Year 3:R | 0.0 |
| Serotype 17 at Year 3:R | 0.0 |
| Serotype 19A at Year 3:R | 2.7 |
| Serotype 19F at Year 3:R | 0.0 |
| Serotype 20 at Year 3:R | 0.0 |
| Serotype 21 at Year 3:R | 0.0 |
| Serotype 22F at Year 3:R | 0.0 |
| Serotype 23A at Year 3:R | 0.0 |
| Serotype 23B at Year 3:R | 0.0 |
| Serotype 31 at Year 3:R | 0.0 |
| Serotype 33A at Year 3:R | 0.0 |
| Serotype 33F at Year 3:R | 0.0 |
| Serotype 34 at Year 3:R | 0.0 |
| Serotype 35B at Year 3:R | 0.0 |
| Serotype 35F at Year 3:R | 0.0 |
| Serotype 38 at Year 3:R | 0.0 |
| Serotype clumps at Year 3:R | 0.0 |
| Serotype Missing/non-viable at Year 3:R | 0.0 |
Antimicrobial susceptibility of S pneumoniae isolates for cefotaxime from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | MEF Population |
|---|---|
| Serotype 3 at Year 1:S | 1.5 |
| Serotype 6C at Year 1:S | 2.2 |
| Serotype 7C at Year 1:S | 0.7 |
| Serotype 9N at Year 1:S | 0.0 |
| Serotype 10 at Year 1:S | 0.7 |
| Serotype 11 at Year 1:S | 0.0 |
| Serotype 12 at Year 1:S | 0.7 |
| Serotype 12F at Year 1:S | 0.0 |
| Serotype 13 at Year 1:S | 0.0 |
| Serotype 15A at Year 1:S | 2.2 |
| Serotype 15B at Year 1:S | 2.2 |
| Serotype 15C at Year 1:S | 0.7 |
| Serotype 15F at Year 1:S | 0.0 |
| Serotype 16 at Year 1:S | 0.7 |
| Serotype 17 at Year 1:S | 0.0 |
| Serotype 19A at Year 1:S | 5.9 |
| Serotype 19F at Year 1:S | 0.0 |
| Serotype 20 at Year 1:S | 0.0 |
| Serotype 21 at Year 1:S | 0.7 |
| Serotype 22F at Year 1:S | 0.7 |
| Serotype 23A at Year 1:S | 0.7 |
| Serotype 23B at Year 1:S | 0.7 |
| Serotype 31 at Year 1:S | 2.2 |
| Serotype 33A at Year 1:S | 0.0 |
| Serotype 33F at Year 1:S | 2.2 |
| Serotype 34 at Year 1:S | 0.0 |
| Serotype 35B at Year 1:S | 3.0 |
| Serotype 35F at Year 1:S | 0.0 |
| Serotype 38 at Year 1:S | 0.0 |
| Serotype clumps at Year 1:S | 1.5 |
| Serotype Missing/non-viable at Year 1:S | 0.7 |
| Serotype 3 at Year 2:S | 2.7 |
| Serotype 6C at Year 2:S | 1.8 |
| Serotype 7C at Year 2:S | 0.0 |
| Serotype 9N at Year 2:S | 0.0 |
| Serotype 10 at Year 2:S | 0.0 |
| Serotype 11 at Year 2:S | 2.7 |
| Serotype 12 at Year 2:S | 0.0 |
| Serotype 12F at Year 2:S | 0.0 |
| Serotype 13 at Year 2:S | 0.0 |
| Serotype 15A at Year 2:S | 0.0 |
| Serotype 15B at Year 2:S | 2.7 |
| Serotype 15C at Year 2:S | 0.0 |
| Serotype 15F at Year 2:S | 0.0 |
| Serotype 16 at Year 2:S | 0.9 |
| Serotype 17 at Year 2:S | 0.0 |
| Serotype 19A at Year 2:S | 2.7 |
| Serotype 19F at Year 2:S | 0.0 |
| Serotype 20 at Year 2:S | 0.0 |
| Serotype 21 at Year 2:S | 4.5 |
| Serotype 22F at Year 2:S | 0.9 |
| Serotype 23A at Year 2:S | 1.8 |
| Serotype 23B at Year 2:S | 2.7 |
| Serotype 31 at Year 2:S | 0.0 |
| Serotype 33A at Year 2:S | 0.0 |
| Serotype 33F at Year 2:S | 0.0 |
| Serotype 34 at Year 2:S | 0.0 |
| Serotype 35B at Year 2:S | 4.5 |
| Serotype 35F at Year 2:S | 0.0 |
| Serotype 38 at Year 2:S | 0.0 |
| Serotype clumps at Year 2:S | 0.9 |
| Serotype Missing/non-viable at Year 2:S | 0.0 |
| Serotype 3 at Year 3:S | 0.9 |
| Serotype 6C at Year 3:S | 0.9 |
| Serotype 7C at Year 3:S | 0.0 |
| Serotype 9N at Year 3:S | 0.0 |
| Serotype 10 at Year 3:S | 0.0 |
| Serotype 11 at Year 3:S | 0.9 |
| Serotype 12 at Year 3:S | 0.0 |
| Serotype 12F at Year 3:S | 0.0 |
| Serotype 13 at Year 3:S | 0.0 |
| Serotype 15A at Year 3:S | 1.8 |
| Serotype 15B at Year 3:S | 0.0 |
| Serotype 15C at Year 3:S | 2.7 |
| Serotype 15F at Year 3:S | 0.0 |
| Serotype 16 at Year 3:S | 0.0 |
| Serotype 17 at Year 3:S | 0.0 |
| Serotype 19A at Year 3:S | 1.8 |
| Serotype 19F at Year 3:S | 2.7 |
| Serotype 20 at Year 3:S | 0.0 |
| Serotype 21 at Year 3:S | 0.9 |
| Serotype 22F at Year 3:S | 0.0 |
| Serotype 23A at Year 3:S | 0.0 |
| Serotype 23B at Year 3:S | 0.9 |
| Serotype 31 at Year 3:S | 0.9 |
| Serotype 33A at Year 3:S | 0.0 |
| Serotype 33F at Year 3:S | 1.8 |
| Serotype 34 at Year 3:S | 0.0 |
| Serotype 35B at Year 3:S | 2.7 |
| Serotype 35F at Year 3:S | 0.9 |
| Serotype 38 at Year 3:S | 0.0 |
| Serotype clumps at Year 3:S | 0.0 |
| Serotype Missing/non-viable at Year 3:S | 0.9 |
| Serotype 3 at Year 1:I | 0.0 |
| Serotype 6C at Year 1:I | 0.0 |
| Serotype 7C at Year 1:I | 0.0 |
| Serotype 9N at Year 1:I | 0.0 |
| Serotype 10 at Year 1:I | 0.0 |
| Serotype 11 at Year 1:I | 0.0 |
| Serotype 12 at Year 1:I | 0.0 |
| Serotype 12F at Year 1:I | 0.0 |
| Serotype 13 at Year 1:I | 0.0 |
| Serotype 15A at Year 1:I | 0.0 |
| Serotype 15B at Year 1:I | 0.0 |
| Serotype 15C at Year 1:I | 0.0 |
| Serotype 15F at Year 1:I | 0.0 |
| Serotype 16 at Year 1:I | 0.0 |
| Serotype 17 at Year 1:I | 0.0 |
| Serotype 19A at Year 1:I | 7.4 |
| Serotype 19F at Year 1:I | 0.7 |
| Serotype 20 at Year 1:I | 0.0 |
| Serotype 21 at Year 1:I | 0.0 |
| Serotype 22F at Year 1:I | 0.0 |
| Serotype 23A at Year 1:I | 0.0 |
| Serotype 23B at Year 1:I | 0.0 |
| Serotype 31 at Year 1:I | 0.0 |
| Serotype 33A at Year 1:I | 0.0 |
| Serotype 33F at Year 1:I | 0.0 |
| Serotype 34 at Year 1:I | 0.0 |
| Serotype 35B at Year 1:I | 0.7 |
| Serotype 35F at Year 1:I | 0.0 |
| Serotype 38 at Year 1:I | 0.0 |
| Serotype clumps at Year 1:I | 0.0 |
| Serotype Missing/non-viable at Year 1:I | 0.0 |
| Serotype 3 at Year 2:I | 0.0 |
| Serotype 6C at Year 2:I | 0.0 |
| Serotype 7C at Year 2:I | 0.0 |
| Serotype 9N at Year 2:I | 0.0 |
| Serotype 10 at Year 2:I | 0.0 |
| Serotype 11 at Year 2:I | 0.9 |
| Serotype 12 at Year 2:I | 0.0 |
| Serotype 12F at Year 2:I | 0.0 |
| Serotype 13 at Year 2:I | 0.0 |
| Serotype 15A at Year 2:I | 0.0 |
| Serotype 15B at Year 2:I | 0.0 |
| Serotype 15C at Year 2:I | 0.0 |
| Serotype 15F at Year 2:I | 0.0 |
| Serotype 16 at Year 2:I | 0.0 |
| Serotype 17 at Year 2:I | 0.0 |
| Serotype 19A at Year 2:I | 4.5 |
| Serotype 19F at Year 2:I | 0.0 |
| Serotype 20 at Year 2:I | 0.0 |
| Serotype 21 at Year 2:I | 0.0 |
| Serotype 22F at Year 2:I | 0.0 |
| Serotype 23A at Year 2:I | 0.0 |
| Serotype 23B at Year 2:I | 0.9 |
| Serotype 31 at Year 2:I | 0.0 |
| Serotype 33A at Year 2:I | 0.0 |
| Serotype 33F at Year 2:I | 0.0 |
| Serotype 34 at Year 2:I | 0.0 |
| Serotype 35B at Year 2:I | 0.9 |
| Serotype 35F at Year 2:I | 0.0 |
| Serotype 38 at Year 2:I | 0.0 |
| Serotype clumps at Year 2:I | 0.0 |
| Serotype Missing/non-viable at Year 2:I | 0.0 |
| Serotype 3 at Year 3:I | 0.0 |
| Serotype 6C at Year 3:I | 0.0 |
| Serotype 7C at Year 3:I | 0.0 |
| Serotype 9N at Year 3:I | 0.0 |
| Serotype 10 at Year 3:I | 0.0 |
| Serotype 11 at Year 3:I | 0.0 |
| Serotype 12 at Year 3:I | 0.0 |
| Serotype 12F at Year 3:I | 0.0 |
| Serotype 13 at Year 3:I | 0.0 |
| Serotype 15A at Year 3:I | 0.0 |
| Serotype 15B at Year 3:I | 0.0 |
| Serotype 15C at Year 3:I | 0.0 |
| Serotype 15F at Year 3:I | 0.0 |
| Serotype 16 at Year 3:I | 0.0 |
| Serotype 17 at Year 3:I | 0.0 |
| Serotype 19A at Year 3:I | 0.0 |
| Serotype 19F at Year 3:I | 0.9 |
| Serotype 20 at Year 3:I | 0.0 |
| Serotype 21 at Year 3:I | 0.0 |
| Serotype 22F at Year 3:I | 0.0 |
| Serotype 23A at Year 3:I | 0.0 |
| Serotype 23B at Year 3:I | 0.0 |
| Serotype 31 at Year 3:I | 0.0 |
| Serotype 33A at Year 3:I | 0.0 |
| Serotype 33F at Year 3:I | 0.0 |
| Serotype 34 at Year 3:I | 0.0 |
| Serotype 35B at Year 3:I | 0.0 |
| Serotype 35F at Year 3:I | 0.0 |
| Serotype 38 at Year 3:I | 0.0 |
| Serotype clumps at Year 3:I | 0.0 |
| Serotype Missing/non-viable at Year 3:I | 0.0 |
| Serotype 3 at Year 1:R | 0.0 |
| Serotype 6C at Year 1:R | 0.0 |
| Serotype 7C at Year 1:R | 0.0 |
| Serotype 9N at Year 1:R | 0.0 |
| Serotype 10 at Year 1:R | 0.0 |
| Serotype 11 at Year 1:R | 0.0 |
| Serotype 12 at Year 1:R | 0.0 |
| Serotype 12F at Year 1:R | 0.0 |
| Serotype 13 at Year 1:R | 0.0 |
| Serotype 15A at Year 1:R | 0.0 |
| Serotype 15B at Year 1:R | 0.0 |
| Serotype 15C at Year 1:R | 0.0 |
| Serotype 15F at Year 1:R | 0.0 |
| Serotype 16 at Year 1:R | 0.0 |
| Serotype 17 at Year 1:R | 0.0 |
| Serotype 19A at Year 1:R | 1.5 |
| Serotype 19F at Year 1:R | 0.0 |
| Serotype 20 at Year 1:R | 0.0 |
| Serotype 21 at Year 1:R | 0.0 |
| Serotype 22F at Year 1:R | 0.0 |
| Serotype 23A at Year 1:R | 0.0 |
| Serotype 23B at Year 1:R | 0.0 |
| Serotype 31 at Year 1:R | 0.0 |
| Serotype 33A at Year 1:R | 0.0 |
| Serotype 33F at Year 1:R | 0.0 |
| Serotype 34 at Year 1:R | 0.0 |
| Serotype 35B at Year 1:R | 0.0 |
| Serotype 35F at Year 1:R | 0.0 |
| Serotype 38 at Year 1:R | 0.0 |
| Serotype clumps at Year 1:R | 0.0 |
| Serotype Missing/non-viable at Year 1:R | 0.0 |
| Serotype 3 at Year 2:R | 0.0 |
| Serotype 6C at Year 2:R | 0.0 |
| Serotype 7C at Year 2:R | 0.0 |
| Serotype 9N at Year 2:R | 0.0 |
| Serotype 10 at Year 2:R | 0.0 |
| Serotype 11 at Year 2:R | 0.0 |
| Serotype 12 at Year 2:R | 0.0 |
| Serotype 12F at Year 2:R | 0.0 |
| Serotype 13 at Year 2:R | 0.0 |
| Serotype 15A at Year 2:R | 0.0 |
| Serotype 15B at Year 2:R | 0.0 |
| Serotype 15C at Year 2:R | 0.0 |
| Serotype 15F at Year 2:R | 0.0 |
| Serotype 16 at Year 2:R | 0.0 |
| Serotype 17 at Year 2:R | 0.0 |
| Serotype 19A at Year 2:R | 0.0 |
| Serotype 19F at Year 2:R | 0.0 |
| Serotype 20 at Year 2:R | 0.0 |
| Serotype 21 at Year 2:R | 0.0 |
| Serotype 22F at Year 2:R | 0.0 |
| Serotype 23A at Year 2:R | 0.0 |
| Serotype 23B at Year 2:R | 0.0 |
| Serotype 31 at Year 2:R | 0.0 |
| Serotype 33A at Year 2:R | 0.0 |
| Serotype 33F at Year 2:R | 0.0 |
| Serotype 34 at Year 2:R | 0.0 |
| Serotype 35B at Year 2:R | 0.0 |
| Serotype 35F at Year 2:R | 0.0 |
| Serotype 38 at Year 2:R | 0.0 |
| Serotype clumps at Year 2:R | 0.0 |
| Serotype Missing/non-viable at Year 2:R | 0.0 |
| Serotype 3 at Year 3:R | 0.0 |
| Serotype 6C at Year 3:R | 0.0 |
| Serotype 7C at Year 3:R | 0.0 |
| Serotype 9N at Year 3:R | 0.0 |
| Serotype 10 at Year 3:R | 0.0 |
| Serotype 11 at Year 3:R | 0.0 |
| Serotype 12 at Year 3:R | 0.0 |
| Serotype 12F at Year 3:R | 0.0 |
| Serotype 13 at Year 3:R | 0.0 |
| Serotype 15A at Year 3:R | 0.0 |
| Serotype 15B at Year 3:R | 0.0 |
| Serotype 15C at Year 3:R | 0.0 |
| Serotype 15F at Year 3:R | 0.0 |
| Serotype 16 at Year 3:R | 0.0 |
| Serotype 17 at Year 3:R | 0.0 |
| Serotype 19A at Year 3:R | 0.0 |
| Serotype 19F at Year 3:R | 0.0 |
| Serotype 20 at Year 3:R | 0.0 |
| Serotype 21 at Year 3:R | 0.0 |
| Serotype 22F at Year 3:R | 0.0 |
| Serotype 23A at Year 3:R | 0.0 |
| Serotype 23B at Year 3:R | 0.0 |
| Serotype 31 at Year 3:R | 0.0 |
| Serotype 33A at Year 3:R | 0.0 |
| Serotype 33F at Year 3:R | 0.0 |
| Serotype 34 at Year 3:R | 0.0 |
| Serotype 35B at Year 3:R | 0.0 |
| Serotype 35F at Year 3:R | 0.0 |
| Serotype 38 at Year 3:R | 0.0 |
| Serotype clumps at Year 3:R | 0.0 |
| Serotype Missing/non-viable at Year 3:R | 0.0 |
Antimicrobial susceptibility of S pneumoniae isolates for ceftriaxone from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | MEF Population |
|---|---|
| Serotype 3 at Year 1:S | 5.9 |
| Serotype 6C at Year 1:S | 6.7 |
| Serotype 7C at Year 1:S | 1.5 |
| Serotype 9N at Year 1:S | 2.2 |
| Serotype 10 at Year 1:S | 3.0 |
| Serotype 11 at Year 1:S | 3.7 |
| Serotype 12 at Year 1:S | 0.7 |
| Serotype 12F at Year 1:S | 0.0 |
| Serotype 13 at Year 1:S | 0.7 |
| Serotype 15A at Year 1:S | 3.7 |
| Serotype 15B at Year 1:S | 4.4 |
| Serotype 15C at Year 1:S | 3.7 |
| Serotype 15F at Year 1:S | 0.0 |
| Serotype 16 at Year 1:S | 1.5 |
| Serotype 17 at Year 1:S | 0.0 |
| Serotype 19A at Year 1:S | 20.7 |
| Serotype 19F at Year 1:S | 1.5 |
| Serotype 20 at Year 1:S | 0.0 |
| Serotype 21 at Year 1:S | 3.0 |
| Serotype 22F at Year 1:S | 1.5 |
| Serotype 23A at Year 1:S | 3.0 |
| Serotype 23B at Year 1:S | 0.7 |
| Serotype 31 at Year 1:S | 2.2 |
| Serotype 33A at Year 1:S | 0.7 |
| Serotype 33F at Year 1:S | 3.0 |
| Serotype 34 at Year 1:S | 0.0 |
| Serotype 35B at Year 1:S | 6.7 |
| Serotype 35F at Year 1:S | 0.0 |
| Serotype 38 at Year 1:S | 0.7 |
| Serotype clumps at Year 1:S | 0.7 |
| Serotype Missing/non-viable at Year 1:S | 0.7 |
| Serotype 3 at Year 2:S | 6.3 |
| Serotype 6C at Year 2:S | 3.6 |
| Serotype 7C at Year 2:S | 0.0 |
| Serotype 9N at Year 2:S | 0.0 |
| Serotype 10 at Year 2:S | 0.9 |
| Serotype 11 at Year 2:S | 6.3 |
| Serotype 12 at Year 2:S | 0.0 |
| Serotype 12F at Year 2:S | 0.9 |
| Serotype 13 at Year 2:S | 0.0 |
| Serotype 15A at Year 2:S | 0.9 |
| Serotype 15B at Year 2:S | 3.6 |
| Serotype 15C at Year 2:S | 2.7 |
| Serotype 15F at Year 2:S | 0.0 |
| Serotype 16 at Year 2:S | 2.7 |
| Serotype 17 at Year 2:S | 1.8 |
| Serotype 19A at Year 2:S | 13.5 |
| Serotype 19F at Year 2:S | 0.9 |
| Serotype 20 at Year 2:S | 0.0 |
| Serotype 21 at Year 2:S | 9.0 |
| Serotype 22F at Year 2:S | 0.9 |
| Serotype 23A at Year 2:S | 4.5 |
| Serotype 23B at Year 2:S | 6.3 |
| Serotype 31 at Year 2:S | 1.8 |
| Serotype 33A at Year 2:S | 0.0 |
| Serotype 33F at Year 2:S | 0.0 |
| Serotype 34 at Year 2:S | 0.9 |
| Serotype 35B at Year 2:S | 11.7 |
| Serotype 35F at Year 2:S | 0.9 |
| Serotype 38 at Year 2:S | 0.9 |
| Serotype clumps at Year 2:S | 0.9 |
| Serotype Missing/non-viable at Year 2:S | 0.9 |
| Serotype 3 at Year 3:S | 6.3 |
| Serotype 6C at Year 3:S | 1.8 |
| Serotype 7C at Year 3:S | 0.0 |
| Serotype 9N at Year 3:S | 0.9 |
| Serotype 10 at Year 3:S | 2.7 |
| Serotype 11 at Year 3:S | 3.6 |
| Serotype 12 at Year 3:S | 0.0 |
| Serotype 12F at Year 3:S | 0.0 |
| Serotype 13 at Year 3:S | 0.0 |
| Serotype 15A at Year 3:S | 6.3 |
| Serotype 15B at Year 3:S | 4.5 |
| Serotype 15C at Year 3:S | 5.4 |
| Serotype 15F at Year 3:S | 0.9 |
| Serotype 16 at Year 3:S | 4.5 |
| Serotype 17 at Year 3:S | 0.9 |
| Serotype 19A at Year 3:S | 5.4 |
| Serotype 19F at Year 3:S | 4.5 |
| Serotype 20 at Year 3:S | 0.9 |
| Serotype 21 at Year 3:S | 5.4 |
| Serotype 22F at Year 3:S | 1.8 |
| Serotype 23A at Year 3:S | 2.7 |
| Serotype 23B at Year 3:S | 8.1 |
| Serotype 31 at Year 3:S | 4.5 |
| Serotype 33A at Year 3:S | 0.0 |
| Serotype 33F at Year 3:S | 1.8 |
| Serotype 34 at Year 3:S | 0.9 |
| Serotype 35B at Year 3:S | 9.9 |
| Serotype 35F at Year 3:S | 1.8 |
| Serotype 38 at Year 3:S | 0.9 |
| Serotype clumps at Year 3:S | 0.0 |
| Serotype Missing/non-viable at Year 3:S | 0.9 |
| Serotype 3 at Year 1:I | 0.0 |
| Serotype 6C at Year 1:I | 0.0 |
| Serotype 7C at Year 1:I | 0.0 |
| Serotype 9N at Year 1:I | 0.0 |
| Serotype 10 at Year 1:I | 0.0 |
| Serotype 11 at Year 1:I | 0.0 |
| Serotype 12 at Year 1:I | 0.0 |
| Serotype 12F at Year 1:I | 0.0 |
| Serotype 13 at Year 1:I | 0.0 |
| Serotype 15A at Year 1:I | 0.0 |
| Serotype 15B at Year 1:I | 0.0 |
| Serotype 15C at Year 1:I | 0.0 |
| Serotype 15F at Year 1:I | 0.0 |
| Serotype 16 at Year 1:I | 0.0 |
| Serotype 17 at Year 1:I | 0.0 |
| Serotype 19A at Year 1:I | 8.1 |
| Serotype 19F at Year 1:I | 0.7 |
| Serotype 20 at Year 1:I | 0.0 |
| Serotype 21 at Year 1:I | 0.0 |
| Serotype 22F at Year 1:I | 0.0 |
| Serotype 23A at Year 1:I | 0.0 |
| Serotype 23B at Year 1:I | 0.0 |
| Serotype 31 at Year 1:I | 0.0 |
| Serotype 33A at Year 1:I | 0.0 |
| Serotype 33F at Year 1:I | 0.0 |
| Serotype 34 at Year 1:I | 0.0 |
| Serotype 35B at Year 1:I | 0.0 |
| Serotype 35F at Year 1:I | 0.0 |
| Serotype 38 at Year 1:I | 0.0 |
| Serotype clumps at Year 1:I | 0.0 |
| Serotype Missing/non-viable at Year 1:I | 0.0 |
| Serotype 3 at Year 2:I | 0.0 |
| Serotype 6C at Year 2:I | 0.0 |
| Serotype 7C at Year 2:I | 0.0 |
| Serotype 9N at Year 2:I | 0.0 |
| Serotype 10 at Year 2:I | 0.0 |
| Serotype 11 at Year 2:I | 0.9 |
| Serotype 12 at Year 2:I | 0.0 |
| Serotype 12F at Year 2:I | 0.0 |
| Serotype 13 at Year 2:I | 0.0 |
| Serotype 15A at Year 2:I | 0.0 |
| Serotype 15B at Year 2:I | 0.0 |
| Serotype 15C at Year 2:I | 0.0 |
| Serotype 15F at Year 2:I | 0.0 |
| Serotype 16 at Year 2:I | 0.0 |
| Serotype 17 at Year 2:I | 0.0 |
| Serotype 19A at Year 2:I | 7.2 |
| Serotype 19F at Year 2:I | 0.0 |
| Serotype 20 at Year 2:I | 0.0 |
| Serotype 21 at Year 2:I | 0.0 |
| Serotype 22F at Year 2:I | 0.0 |
| Serotype 23A at Year 2:I | 0.0 |
| Serotype 23B at Year 2:I | 0.9 |
| Serotype 31 at Year 2:I | 0.0 |
| Serotype 33A at Year 2:I | 0.0 |
| Serotype 33F at Year 2:I | 0.0 |
| Serotype 34 at Year 2:I | 0.0 |
| Serotype 35B at Year 2:I | 0.0 |
| Serotype 35F at Year 2:I | 0.0 |
| Serotype 38 at Year 2:I | 0.0 |
| Serotype clumps at Year 2:I | 0.0 |
| Serotype Missing/non-viable at Year 2:I | 0.0 |
| Serotype 3 at Year 3:I | 0.9 |
| Serotype 6C at Year 3:I | 0.0 |
| Serotype 7C at Year 3:I | 0.0 |
| Serotype 9N at Year 3:I | 0.0 |
| Serotype 10 at Year 3:I | 0.0 |
| Serotype 11 at Year 3:I | 0.0 |
| Serotype 12 at Year 3:I | 0.0 |
| Serotype 12F at Year 3:I | 0.0 |
| Serotype 13 at Year 3:I | 0.0 |
| Serotype 15A at Year 3:I | 0.0 |
| Serotype 15B at Year 3:I | 0.0 |
| Serotype 15C at Year 3:I | 0.0 |
| Serotype 15F at Year 3:I | 0.0 |
| Serotype 16 at Year 3:I | 0.0 |
| Serotype 17 at Year 3:I | 0.0 |
| Serotype 19A at Year 3:I | 2.7 |
| Serotype 19F at Year 3:I | 0.9 |
| Serotype 20 at Year 3:I | 0.0 |
| Serotype 21 at Year 3:I | 0.0 |
| Serotype 22F at Year 3:I | 0.0 |
| Serotype 23A at Year 3:I | 0.0 |
| Serotype 23B at Year 3:I | 0.0 |
| Serotype 31 at Year 3:I | 0.0 |
| Serotype 33A at Year 3:I | 0.0 |
| Serotype 33F at Year 3:I | 0.0 |
| Serotype 34 at Year 3:I | 0.0 |
| Serotype 35B at Year 3:I | 0.0 |
| Serotype 35F at Year 3:I | 0.0 |
| Serotype 38 at Year 3:I | 0.0 |
| Serotype clumps at Year 3:I | 0.0 |
| Serotype Missing/non-viable at Year 3:I | 0.0 |
| Serotype 3 at Year 1:R | 0.0 |
| Serotype 6C at Year 1:R | 0.0 |
| Serotype 7C at Year 1:R | 0.0 |
| Serotype 9N at Year 1:R | 0.0 |
| Serotype 10 at Year 1:R | 0.0 |
| Serotype 11 at Year 1:R | 0.0 |
| Serotype 12 at Year 1:R | 0.0 |
| Serotype 12F at Year 1:R | 0.0 |
| Serotype 13 at Year 1:R | 0.0 |
| Serotype 15A at Year 1:R | 0.0 |
| Serotype 15B at Year 1:R | 0.0 |
| Serotype 15C at Year 1:R | 0.0 |
| Serotype 15F at Year 1:R | 0.0 |
| Serotype 16 at Year 1:R | 0.0 |
| Serotype 17 at Year 1:R | 0.0 |
| Serotype 19A at Year 1:R | 1.5 |
| Serotype 19F at Year 1:R | 0.0 |
| Serotype 20 at Year 1:R | 0.0 |
| Serotype 21 at Year 1:R | 0.0 |
| Serotype 22F at Year 1:R | 0.0 |
| Serotype 23A at Year 1:R | 0.0 |
| Serotype 23B at Year 1:R | 0.0 |
| Serotype 31 at Year 1:R | 0.0 |
| Serotype 33A at Year 1:R | 0.0 |
| Serotype 33F at Year 1:R | 0.0 |
| Serotype 34 at Year 1:R | 0.0 |
| Serotype 35B at Year 1:R | 0.0 |
| Serotype 35F at Year 1:R | 0.0 |
| Serotype 38 at Year 1:R | 0.0 |
| Serotype clumps at Year 1:R | 0.0 |
| Serotype Missing/non-viable at Year 1:R | 0.0 |
| Serotype 3 at Year 2:R | 0.0 |
| Serotype 6C at Year 2:R | 0.0 |
| Serotype 7C at Year 2:R | 0.0 |
| Serotype 9N at Year 2:R | 0.0 |
| Serotype 10 at Year 2:R | 0.0 |
| Serotype 11 at Year 2:R | 0.0 |
| Serotype 12 at Year 2:R | 0.0 |
| Serotype 12F at Year 2:R | 0.0 |
| Serotype 13 at Year 2:R | 0.0 |
| Serotype 15A at Year 2:R | 0.0 |
| Serotype 15B at Year 2:R | 0.0 |
| Serotype 15C at Year 2:R | 0.0 |
| Serotype 15F at Year 2:R | 0.0 |
| Serotype 16 at Year 2:R | 0.0 |
| Serotype 17 at Year 2:R | 0.0 |
| Serotype 19A at Year 2:R | 0.0 |
| Serotype 19F at Year 2:R | 0.0 |
| Serotype 20 at Year 2:R | 0.0 |
| Serotype 21 at Year 2:R | 0.0 |
| Serotype 22F at Year 2:R | 0.0 |
| Serotype 23A at Year 2:R | 0.0 |
| Serotype 23B at Year 2:R | 0.0 |
| Serotype 31 at Year 2:R | 0.0 |
| Serotype 33A at Year 2:R | 0.0 |
| Serotype 33F at Year 2:R | 0.0 |
| Serotype 34 at Year 2:R | 0.0 |
| Serotype 35B at Year 2:R | 0.0 |
| Serotype 35F at Year 2:R | 0.0 |
| Serotype 38 at Year 2:R | 0.0 |
| Serotype clumps at Year 2:R | 0.0 |
| Serotype Missing/non-viable at Year 2:R | 0.0 |
| Serotype 3 at Year 3:R | 0.0 |
| Serotype 6C at Year 3:R | 0.0 |
| Serotype 7C at Year 3:R | 0.0 |
| Serotype 9N at Year 3:R | 0.0 |
| Serotype 10 at Year 3:R | 0.0 |
| Serotype 11 at Year 3:R | 0.0 |
| Serotype 12 at Year 3:R | 0.0 |
| Serotype 12F at Year 3:R | 0.0 |
| Serotype 13 at Year 3:R | 0.0 |
| Serotype 15A at Year 3:R | 0.0 |
| Serotype 15B at Year 3:R | 0.0 |
| Serotype 15C at Year 3:R | 0.0 |
| Serotype 15F at Year 3:R | 0.0 |
| Serotype 16 at Year 3:R | 0.0 |
| Serotype 17 at Year 3:R | 0.0 |
| Serotype 19A at Year 3:R | 0.9 |
| Serotype 19F at Year 3:R | 0.0 |
| Serotype 20 at Year 3:R | 0.0 |
| Serotype 21 at Year 3:R | 0.0 |
| Serotype 22F at Year 3:R | 0.9 |
| Serotype 23A at Year 3:R | 0.0 |
| Serotype 23B at Year 3:R | 0.0 |
| Serotype 31 at Year 3:R | 0.0 |
| Serotype 33A at Year 3:R | 0.0 |
| Serotype 33F at Year 3:R | 0.0 |
| Serotype 34 at Year 3:R | 0.0 |
| Serotype 35B at Year 3:R | 0.0 |
| Serotype 35F at Year 3:R | 0.0 |
| Serotype 38 at Year 3:R | 0.0 |
| Serotype clumps at Year 3:R | 0.0 |
| Serotype Missing/non-viable at Year 3:R | 0.0 |
Antimicrobial susceptibility of S pneumoniae isolates for clindamycin from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | MEF Population |
|---|---|
| Serotype 3 at Year 1:S | 4.4 |
| Serotype 9N at Year 1:S | 0.0 |
| Serotype 10 at Year 1:S | 1.5 |
| Serotype 11 at Year 1:S | 1.5 |
| Serotype 12 at Year 1:S | 0.7 |
| Serotype 12F at Year 1:S | 0.0 |
| Serotype 13 at Year 1:S | 0.0 |
| Serotype 15A at Year 1:S | 0.7 |
| Serotype 15B at Year 1:S | 2.2 |
| Serotype 15C at Year 1:S | 3.0 |
| Serotype 15F at Year 1:S | 0.0 |
| Serotype 16 at Year 1:S | 0.0 |
| Serotype 17 at Year 1:S | 0.0 |
| Serotype 19A at Year 1:S | 3.0 |
| Serotype 19F at Year 1:S | 0.7 |
| Serotype 20 at Year 1:S | 0.0 |
| Serotype 21 at Year 1:S | 1.5 |
| Serotype 22F at Year 1:S | 0.0 |
| Serotype 23A at Year 1:S | 2.2 |
| Serotype 23B at Year 1:S | 0.7 |
| Serotype 31 at Year 1:S | 1.5 |
| Serotype 33A at Year 1:S | 0.7 |
| Serotype 33F at Year 1:S | 0.7 |
| Serotype 34 at Year 1:S | 0.0 |
| Serotype 35B at Year 1:S | 5.9 |
| Serotype 35F at Year 1:S | 0.0 |
| Serotype 38 at Year 1:S | 0.0 |
| Serotype clumps at Year 1:S | 0.0 |
| Serotype Missing/non-viable at Year 1:S | 0.0 |
| Serotype 3 at Year 2:S | 4.5 |
| Serotype 6C at Year 2:S | 2.7 |
| Serotype 7C at Year 2:S | 0.0 |
| Serotype 9N at Year 2:S | 0.0 |
| Serotype 10 at Year 2:S | 0.9 |
| Serotype 11 at Year 2:S | 3.6 |
| Serotype 12 at Year 2:S | 0.0 |
| Serotype 12F at Year 2:S | 0.9 |
| Serotype 13 at Year 2:S | 0.0 |
| Serotype 15A at Year 2:S | 0.0 |
| Serotype 15B at Year 2:S | 1.8 |
| Serotype 15C at Year 2:S | 2.7 |
| Serotype 15F at Year 2:S | 0.0 |
| Serotype 16 at Year 2:S | 1.8 |
| Serotype 17 at Year 2:S | 1.8 |
| Serotype 19A at Year 2:S | 2.7 |
| Serotype 19F at Year 2:S | 0.9 |
| Serotype 20 at Year 2:S | 0.0 |
| Serotype 21 at Year 2:S | 5.4 |
| Serotype 22F at Year 2:S | 0.0 |
| Serotype 23A at Year 2:S | 1.8 |
| Serotype 23B at Year 2:S | 6.3 |
| Serotype 31 at Year 2:S | 1.8 |
| Serotype 33A at Year 2:S | 0.0 |
| Serotype 33F at Year 2:S | 0.0 |
| Serotype 34 at Year 2:S | 0.9 |
| Serotype 35B at Year 2:S | 9.0 |
| Serotype 35F at Year 2:S | 0.9 |
| Serotype 38 at Year 2:S | 0.9 |
| Serotype clumps at Year 2:S | 0.0 |
| Serotype Missing/non-viable at Year 2:S | 0.9 |
| Serotype 3 at Year 3:S | 3.6 |
| Serotype 6C at Year 3:S | 0.0 |
| Serotype 7C at Year 3:S | 0.0 |
| Serotype 9N at Year 3:S | 0.9 |
| Serotype 10 at Year 3:S | 1.8 |
| Serotype 11 at Year 3:S | 1.8 |
| Serotype 12 at Year 3:S | 0.0 |
| Serotype 12F at Year 3:S | 0.0 |
| Serotype 13 at Year 3:S | 0.0 |
| Serotype 15A at Year 3:S | 2.7 |
| Serotype 15B at Year 3:S | 2.7 |
| Serotype 15C at Year 3:S | 2.7 |
| Serotype 15F at Year 3:S | 0.0 |
| Serotype 16 at Year 3:S | 3.6 |
| Serotype 17 at Year 3:S | 0.9 |
| Serotype 19A at Year 3:S | 1.8 |
| Serotype 19F at Year 3:S | 2.7 |
| Serotype 20 at Year 3:S | 0.9 |
| Serotype 21 at Year 3:S | 1.8 |
| Serotype 22F at Year 3:S | 0.0 |
| Serotype 23A at Year 3:S | 2.7 |
| Serotype 23B at Year 3:S | 7.2 |
| Serotype 31 at Year 3:S | 2.7 |
| Serotype 33A at Year 3:S | 0.0 |
| Serotype 33F at Year 3:S | 1.8 |
| Serotype 34 at Year 3:S | 0.0 |
| Serotype 35B at Year 3:S | 6.3 |
| Serotype 35F at Year 3:S | 0.9 |
| Serotype 38 at Year 3:S | 0.9 |
| Serotype clumps at Year 3:S | 0.0 |
| Serotype Missing/non-viable at Year 3:S | 1.8 |
| Serotype 6C at Year 1:S | 4.4 |
| Serotype 7C at Year 1:S | 0.0 |
| Serotype 3 at Year 1:I | 0.0 |
| Serotype 6C at Year 1:I | 0.0 |
| Serotype 7C at Year 1:I | 0.0 |
| Serotype 9N at Year 1:I | 0.7 |
| Serotype 10 at Year 1:I | 0.0 |
| Serotype 11 at Year 1:I | 0.0 |
| Serotype 12 at Year 1:I | 0.0 |
| Serotype 12F at Year 1:I | 0.0 |
| Serotype 13 at Year 1:I | 0.0 |
| Serotype 15A at Year 1:I | 0.0 |
| Serotype 15B at Year 1:I | 0.0 |
| Serotype 15C at Year 1:I | 0.0 |
| Serotype 15F at Year 1:I | 0.0 |
| Serotype 16 at Year 1:I | 0.0 |
| Serotype 17 at Year 1:I | 0.0 |
| Serotype 19A at Year 1:I | 5.2 |
| Serotype 19F at Year 1:I | 0.0 |
| Serotype 20 at Year 1:I | 0.0 |
| Serotype 21 at Year 1:I | 0.0 |
| Serotype 22F at Year 1:I | 0.0 |
| Serotype 23A at Year 1:I | 0.0 |
| Serotype 23B at Year 1:I | 0.0 |
| Serotype 31 at Year 1:I | 0.0 |
| Serotype 33A at Year 1:I | 0.0 |
| Serotype 33F at Year 1:I | 0.7 |
| Serotype 34 at Year 1:I | 0.0 |
| Serotype 35B at Year 1:I | 0.0 |
| Serotype 35F at Year 1:I | 0.0 |
| Serotype 38 at Year 1:I | 0.0 |
| Serotype clumps at Year 1:I | 0.0 |
| Serotype Missing/non-viable at Year 1:I | 0.0 |
| Serotype 3 at Year 2:I | 0.0 |
| Serotype 6C at Year 2:I | 0.0 |
| Serotype 7C at Year 2:I | 0.0 |
| Serotype 9N at Year 2:I | 0.0 |
| Serotype 10 at Year 2:I | 0.0 |
| Serotype 11 at Year 2:I | 0.0 |
| Serotype 12 at Year 2:I | 0.0 |
| Serotype 12F at Year 2:I | 0.0 |
| Serotype 13 at Year 2:I | 0.0 |
| Serotype 15A at Year 2:I | 0.0 |
| Serotype 15B at Year 2:I | 0.0 |
| Serotype 15C at Year 2:I | 0.0 |
| Serotype 15F at Year 2:I | 0.0 |
| Serotype 16 at Year 2:I | 0.0 |
| Serotype 17 at Year 2:I | 0.0 |
| Serotype 19A at Year 2:I | 0.9 |
| Serotype 19F at Year 2:I | 0.0 |
| Serotype 20 at Year 2:I | 0.0 |
| Serotype 21 at Year 2:I | 0.0 |
| Serotype 22F at Year 2:I | 0.0 |
| Serotype 23A at Year 2:I | 0.9 |
| Serotype 23B at Year 2:I | 0.0 |
| Serotype 31 at Year 2:I | 0.0 |
| Serotype 33A at Year 2:I | 0.0 |
| Serotype 33F at Year 2:I | 0.0 |
| Serotype 34 at Year 2:I | 0.0 |
| Serotype 35B at Year 2:I1 | 0.9 |
| Serotype 35F at Year 2:I | 0.0 |
| Serotype 38 at Year 2:I | 0.0 |
| Serotype clumps at Year 2:I | 0.0 |
| Serotype Missing/non-viable at Year 2:I | 0.0 |
| Serotype 3 at Year 3:I | 0.0 |
| Serotype 6C at Year 3:I | 0.0 |
| Serotype 7C at Year 3:I | 0.0 |
| Serotype 9N at Year 3:I | 0.0 |
| Serotype 10 at Year 3:I | 0.0 |
| Serotype 11 at Year 3:I | 0.0 |
| Serotype 12 at Year 3:I | 0.0 |
| Serotype 12F at Year 3:I | 0.0 |
| Serotype 13 at Year 3:I | 0.0 |
| Serotype 15A at Year 3:I | 0.0 |
| Serotype 15B at Year 3:I | 0.9 |
| Serotype 15C at Year 3:I | 0.0 |
| Serotype 15F at Year 3:I | 0.0 |
| Serotype 16 at Year 3:I | 0.0 |
| Serotype 17 at Year 3:I | 0.0 |
| Serotype 19A at Year 3:I | 0.0 |
| Serotype 19F at Year 3:I | 0.9 |
| Serotype 20 at Year 3:I | 0.0 |
| Serotype 21 at Year 3:I | 0.0 |
| Serotype 22F at Year 3:I | 0.0 |
| Serotype 23A at Year 3:I | 0.0 |
| Serotype 23B at Year 3:I | 0.0 |
| Serotype 31 at Year 3:I | 0.0 |
| Serotype 33A at Year 3:I | 0.0 |
| Serotype 33F at Year 3:I | 0.0 |
| Serotype 34 at Year 3:I | 0.0 |
| Serotype 35B at Year 3:I | 2.7 |
| Serotype 35F at Year 3:I | 0.0 |
| Serotype 38 at Year 3:I | 0.0 |
| Serotype clumps at Year 3:I | 0.0 |
| Serotype Missing/non-viable at Year 3:I | 0.0 |
| Serotype 3 at Year 1:R | 0.0 |
| Serotype 6C at Year 1:R | 0.0 |
| Serotype 7C at Year 1:R | 0.0 |
| Serotype 9N at Year 1:R | 0.0 |
| Serotype 10 at Year 1:R | 0.0 |
| Serotype 11 at Year 1:R | 0.0 |
| Serotype 12 at Year 1:R | 0.0 |
| Serotype 12F at Year 1:R | 0.0 |
| Serotype 13 at Year 1:R | 0.0 |
| Serotype 15A at Year 1:R | 2.2 |
| Serotype 15B at Year 1:R | 0.0 |
| Serotype 15C at Year 1:R | 0.0 |
| Serotype 15F at Year 1:R | 0.0 |
| Serotype 16 at Year 1:R | 0.0 |
| Serotype 17 at Year 1:R | 0.0 |
| Serotype 19A at Year 1:R | 12.6 |
| Serotype 19F at Year 1:R | 0.0 |
| Serotype 20 at Year 1:R | 0.0 |
| Serotype 21 at Year 1:R | 0.0 |
| Serotype 22F at Year 1:R | 0.0 |
| Serotype 23A at Year 1:R | 0.0 |
| Serotype 23B at Year 1:R | 0.0 |
| Serotype 31 at Year 1:R | 0.0 |
| Serotype 33A at Year 1:R | 0.0 |
| Serotype 33F at Year 1:R | 0.0 |
| Serotype 34 at Year 1:R | 0.0 |
| Serotype 35B at Year 1:R | 0.0 |
| Serotype 35F at Year 1:R | 0.0 |
| Serotype 38 at Year 1:R | 0.0 |
| Serotype clumps at Year 1:R | 0.0 |
| Serotype Missing/non-viable at Year 1:R | 0.0 |
| Serotype 3 at Year 2:R | 0.0 |
| Serotype 6C at Year 2:R | 0.0 |
| Serotype 7C at Year 2:R | 0.0 |
| Serotype 9N at Year 2:R | 0.0 |
| Serotype 10 at Year 2:R | 0.0 |
| Serotype 11 at Year 2:R | 0.9 |
| Serotype 12 at Year 2:R | 0.0 |
| Serotype 12F at Year 2:R | 0.0 |
| Serotype 13 at Year 2:R | 0.0 |
| Serotype 15A at Year 2:R | 0.9 |
| Serotype 15B at Year 2:R | 0.0 |
| Serotype 15C at Year 2:R | 0.0 |
| Serotype 15F at Year 2:R | 0.0 |
| Serotype 16 at Year 2:R | 0.0 |
| Serotype 17 at Year 2:R | 0.0 |
| Serotype 19A at Year 2:R | 6.3 |
| Serotype 19F at Year 2:R | 0.0 |
| Serotype 20 at Year 2:R | 0.0 |
| Serotype 21 at Year 2:R | 0.0 |
| Serotype 22F at Year 2:R | 0.0 |
| Serotype 23A at Year 2:R | 0.0 |
| Serotype 23B at Year 2:R | 0.0 |
| Serotype 31 at Year 2:R | 0.0 |
| Serotype 33A at Year 2:R | 0.0 |
| Serotype 33F at Year 2:R | 0.0 |
| Serotype 34 at Year 2:R | 0.0 |
| Serotype 35B at Year 2:R | 0.9 |
| Serotype 35F at Year 2:R | 0.0 |
| Serotype 38 at Year 2:R | 0.0 |
| Serotype clumps at Year 2:R | 0.0 |
| Serotype Missing/non-viable at Year 2:R | 0.0 |
| Serotype 3 at Year 3:R | 0.0 |
| Serotype 6C at Year 3:R | 0.0 |
| Serotype 7C at Year 3:R | 0.0 |
| Serotype 9N at Year 3:R | 0.0 |
| Serotype 10 at Year 3:R | 0.0 |
| Serotype 11 at Year 3:R | 0.0 |
| Serotype 12 at Year 3:R | 0.0 |
| Serotype 12F at Year 3:R | 0.0 |
| Serotype 13 at Year 3:R | 0.0 |
| Serotype 15A at Year 3:R | 0.9 |
| Serotype 15B at Year 3:R | 0.0 |
| Serotype 15C at Year 3:R | 0.0 |
| Serotype 15F at Year 3:R | 0.0 |
| Serotype 16 at Year 3:R | 0.0 |
| Serotype 17 at Year 3:R | 0.0 |
| Serotype 19A at Year 3:R | 4.5 |
| Serotype 19F at Year 3:R | 0.9 |
| Serotype 20 at Year 3:R | 0.0 |
| Serotype 21 at Year 3:R | 0.0 |
| Serotype 22F at Year 3:R | 0.0 |
| Serotype 23A at Year 3:R | 0.0 |
| Serotype 23B at Year 3:R | 0.0 |
| Serotype 31 at Year 3:R | 0.0 |
| Serotype 33A at Year 3:R | 0.0 |
| Serotype 33F at Year 3:R | 0.0 |
| Serotype 34 at Year 3:R | 0.0 |
| Serotype 35B at Year 3:R | 0.9 |
| Serotype 35F at Year 3:R | 0.0 |
| Serotype 38 at Year 3:R | 0.0 |
| Serotype clumps at Year 3:R | 0.0 |
| Serotype Missing/non-viable at Year 3:R | 0.0 |
Antimicrobial susceptibility of S pneumoniae isolates for erythromycin from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19A, 19F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | MEF Population |
|---|---|
| Serotype 3 at Year 1:S | 5.9 |
| Serotype 6C at Year 1:S | 4.4 |
| Serotype 7C at Year 1:S | 1.5 |
| Serotype 9N at Year 1:S | 2.2 |
| Serotype 10 at Year 1:S | 3.0 |
| Serotype 11 at Year 1:S | 3.0 |
| Serotype 12 at Year 1:S | 0.7 |
| Serotype 12F at Year 1:S | 0.0 |
| Serotype 13 at Year 1:S | 0.0 |
| Serotype 15A at Year 1:S | 1.5 |
| Serotype 15B at Year 1:S | 3.0 |
| Serotype 15C at Year 1:S | 1.5 |
| Serotype 15F at Year 1:S | 0.0 |
| Serotype 16 at Year 1:S | 1.5 |
| Serotype 17 at Year 1:S | 0.0 |
| Serotype 19A at Year 1:S | 1.5 |
| Serotype 19F at Year 1:S | 0.7 |
| Serotype 20 at Year 1:S | 0.0 |
| Serotype 21 at Year 1:S | 3.0 |
| Serotype 22F at Year 1:S | 1.5 |
| Serotype 23A at Year 1:S | 3.0 |
| Serotype 23B at Year 1:S | 0.7 |
| Serotype 31 at Year 1:S | 0.7 |
| Serotype 33A at Year 1:S | 0.0 |
| Serotype 33F at Year 1:S | 0.7 |
| Serotype 34 at Year 1:S | 0.0 |
| Serotype 35B at Year 1:S | 2.2 |
| Serotype 35F at Year 1:S | 0.0 |
| Serotype 38 at Year 1:S | 0.7 |
| Serotype clumps at Year 1:S | 0.7 |
| Serotype Missing/non-viable at Year 1:S | 0.7 |
| Serotype 3 at Year 2:S | 5.4 |
| Serotype 6C at Year 2:S | 2.7 |
| Serotype 7C at Year 2:S | 0.0 |
| Serotype 9N at Year 2:S | 0.0 |
| Serotype 10 at Year 2:S | 0.0 |
| Serotype 11 at Year 2:S | 3.6 |
| Serotype 12 at Year 2:S | 0.0 |
| Serotype 12F at Year 2:S | 0.9 |
| Serotype 13 at Year 2:S | 0.0 |
| Serotype 15A at Year 2:S | 0.0 |
| Serotype 15B at Year 2:S | 1.8 |
| Serotype 15C at Year 2:S | 0.9 |
| Serotype 15F at Year 2:S | 0.0 |
| Serotype 16 at Year 2:S | 2.7 |
| Serotype 17 at Year 2:S | 1.8 |
| Serotype 19A at Year 2:S | 3.6 |
| Serotype 19F at Year 2:S | 0.9 |
| Serotype 20 at Year 2:S | 0.0 |
| Serotype 21 at Year 2:S | 9.0 |
| Serotype 22F at Year 2:S | 0.9 |
| Serotype 23A at Year 2:S | 3.6 |
| Serotype 23B at Year 2:S | 5.4 |
| Serotype 31 at Year 2:S | 1.8 |
| Serotype 33A at Year 2:S | 0.0 |
| Serotype 33F at Year 2:S | 0.0 |
| Serotype 34 at Year 2:S | 0.9 |
| Serotype 35B at Year 2:S | 3.6 |
| Serotype 35F at Year 2:S | 0.9 |
| Serotype 38 at Year 2:S | 0.9 |
| Serotype clumps at Year 2:S | 0.9 |
| Serotype Missing/non-viable at Year 2:S | 0.9 |
| Serotype 3 at Year 3:S | 5.4 |
| Serotype 6C at Year 3:S | 1.8 |
| Serotype 7C at Year 3:S | 0.0 |
| Serotype 9N at Year 3:S | 0.9 |
| Serotype 10 at Year 3:S | 2.7 |
| Serotype 11 at Year 3:S | 0.9 |
| Serotype 12 at Year 3:S | 0.0 |
| Serotype 12F at Year 3:S | 0.0 |
| Serotype 13 at Year 3:S | 0.0 |
| Serotype 15A at Year 3:S | 2.7 |
| Serotype 15B at Year 3:S | 1.8 |
| Serotype 15C at Year 3:S | 3.6 |
| Serotype 15F at Year 3:S | 0.0 |
| Serotype 16 at Year 3:S | 3.6 |
| Serotype 17 at Year 3:S | 0.9 |
| Serotype 19A at Year 3:S | 0.9 |
| Serotype 19F at Year 3:S | 2.7 |
| Serotype 20 at Year 3:S | 0.9 |
| Serotype 21 at Year 3:S | 4.5 |
| Serotype 22F at Year 3:S | 1.8 |
| Serotype 23A at Year 3:S | 2.7 |
| Serotype 23B at Year 3:S | 3.6 |
| Serotype 31 at Year 3:S | 4.5 |
| Serotype 33A at Year 3:S | 0.0 |
| Serotype 33F at Year 3:S | 0.0 |
| Serotype 34 at Year 3:S | 0.9 |
| Serotype 35B at Year 3:S | 2.7 |
| Serotype 35F at Year 3:S | 0.9 |
| Serotype 38 at Year 3:S | 0.9 |
| Serotype clumps at Year 3:S | 0.0 |
| Serotype Missing/non-viable at Year 3:S | 0.9 |
| Serotype 3 at Year 1:I | 0.0 |
| Serotype 6C at Year 1:I | 0.0 |
| Serotype 7C at Year 1:I | 0.0 |
| Serotype 9N at Year 1:I | 0.0 |
| Serotype 10 at Year 1:I | 0.0 |
| Serotype 11 at Year 1:I | 0.7 |
| Serotype 12 at Year 1:I | 0.0 |
| Serotype 12F at Year 1:I | 0.0 |
| Serotype 13 at Year 1:I | 0.7 |
| Serotype 15A at Year 1:I | 0.0 |
| Serotype 15B at Year 1:I | 0.0 |
| Serotype 15C at Year 1:I | 0.7 |
| Serotype 15F at Year 1:I | 0.0 |
| Serotype 16 at Year 1:I | 0.0 |
| Serotype 17 at Year 1:I | 0.0 |
| Serotype 19A at Year 1:I | 14.1 |
| Serotype 19F at Year 1:I | 0.7 |
| Serotype 20 at Year 1:I | 0.0 |
| Serotype 21 at Year 1:I | 0.0 |
| Serotype 22F at Year 1:I | 0.0 |
| Serotype 23A at Year 1:I | 0.0 |
| Serotype 23B at Year 1:I | 0.0 |
| Serotype 31 at Year 1:I | 0.7 |
| Serotype 33A at Year 1:I | 0.0 |
| Serotype 33F at Year 1:I | 0.0 |
| Serotype 34 at Year 1:I | 0.0 |
| Serotype 35B at Year 1:I | 0.0 |
| Serotype 35F at Year 1:I | 0.0 |
| Serotype 38 at Year 1:I | 0.0 |
| Serotype clumps at Year 1:I | 0.0 |
| Serotype Missing/non-viable at Year 1:I | 0.0 |
| Serotype 3 at Year 2:I | 0.9 |
| Serotype 6C at Year 2:I | 0.0 |
| Serotype 7C at Year 2:I | 0.0 |
| Serotype 9N at Year 2:I | 0.0 |
| Serotype 10 at Year 2:I | 0.0 |
| Serotype 11 at Year 2:I | 0.9 |
| Serotype 12 at Year 2:I | 0.0 |
| Serotype 12F at Year 2:I | 0.0 |
| Serotype 13 at Year 2:I | 0.0 |
| Serotype 15A at Year 2:I | 0.0 |
| Serotype 15B at Year 2:I | 2.7 |
| Serotype 15C at Year 2:I | 0.0 |
| Serotype 15F at Year 2:I | 0.0 |
| Serotype 16 at Year 2:I | 0.0 |
| Serotype 17 at Year 2:I | 0.0 |
| Serotype 19A at Year 2:I | 12.6 |
| Serotype 19F at Year 2:I | 0.0 |
| Serotype 20 at Year 2:I | 0.0 |
| Serotype 21 at Year 2:I | 0.0 |
| Serotype 22F at Year 2:I | 0.0 |
| Serotype 23A at Year 2:I | 0.0 |
| Serotype 23B at Year 2:I | 0.9 |
| Serotype 31 at Year 2:I | 0.0 |
| Serotype 33A at Year 2:I | 0.0 |
| Serotype 33F at Year 2:I | 0.0 |
| Serotype 34 at Year 2:I | 0.0 |
| Serotype 35B at Year 2:I | 0.9 |
| Serotype 35F at Year 2:I | 0.0 |
| Serotype 38 at Year 2:I | 0.0 |
| Serotype clumps at Year 2:I | 0.0 |
| Serotype Missing/non-viable at Year 2:I | 0.0 |
| Serotype 3 at Year 3:I | 1.8 |
| Serotype 6C at Year 3:I | 0.0 |
| Serotype 7C at Year 3:I | 0.0 |
| Serotype 9N at Year 3:I | 0.0 |
| Serotype 10 at Year 3:I | 0.0 |
| Serotype 11 at Year 3:I | 0.9 |
| Serotype 12 at Year 3:I | 0.0 |
| Serotype 12F at Year 3:I | 0.0 |
| Serotype 13 at Year 3:I | 0.0 |
| Serotype 15A at Year 3:I | 2.7 |
| Serotype 15B at Year 3:I | 0.9 |
| Serotype 15C at Year 3:I | 0.9 |
| Serotype 15F at Year 3:I | 0.9 |
| Serotype 16 at Year 3:I | 0.0 |
| Serotype 17 at Year 3:I | 0.0 |
| Serotype 19A at Year 3:I | 2.7 |
| Serotype 19F at Year 3:I | 1.8 |
| Serotype 20 at Year 3:I | 0.0 |
| Serotype 21 at Year 3:I | 0.0 |
| Serotype 22F at Year 3:I | 0.9 |
| Serotype 23A at Year 3:I | 0.0 |
| Serotype 23B at Year 3:I | 1.8 |
| Serotype 31 at Year 3:I | 0.0 |
| Serotype 33A at Year 3:I | 0.0 |
| Serotype 33F at Year 3:I | 0.0 |
| Serotype 34 at Year 3:I | 0.0 |
| Serotype 35B at Year 3:I | 2.7 |
| Serotype 35F at Year 3:I | 0.0 |
| Serotype 38 at Year 3:I | 0.0 |
| Serotype clumps at Year 3:I | 0.0 |
| Serotype Missing/non-viable at Year 3:I | 0.0 |
| Serotype 3 at Year 1:R | 0.0 |
| Serotype 6C at Year 1:R | 2.2 |
| Serotype 7C at Year 1:R | 0.0 |
| Serotype 9N at Year 1:R | 0.0 |
| Serotype 10 at Year 1:R | 0.0 |
| Serotype 11 at Year 1:R | 0.0 |
| Serotype 12 at Year 1:R | 0.0 |
| Serotype 12F at Year 1:R | 0.0 |
| Serotype 13 at Year 1:R | 0.0 |
| Serotype 15A at Year 1:R | 1.5 |
| Serotype 15B at Year 1:R | 0.7 |
| Serotype 15C at Year 1:R | 1.5 |
| Serotype 15F at Year 1:R | 0.0 |
| Serotype 16 at Year 1:R | 0.0 |
| Serotype 17 at Year 1:R | 0.0 |
| Serotype 19A at Year 1:R | 14.8 |
| Serotype 19F at Year 1:R | 0.7 |
| Serotype 20 at Year 1:R | 0.0 |
| Serotype 21 at Year 1:R | 0.0 |
| Serotype 22F at Year 1:R | 0.0 |
| Serotype 23A at Year 1:R | 0.0 |
| Serotype 23B at Year 1:R | 0.0 |
| Serotype 31 at Year 1:R | 0.7 |
| Serotype 33A at Year 1:R | 0.7 |
| Serotype 33F at Year 1:R | 2.2 |
| Serotype 34 at Year 1:R | 0.0 |
| Serotype 35B at Year 1:R | 4.4 |
| Serotype 35F at Year 1:R | 0.0 |
| Serotype 38 at Year 1:R | 0.0 |
| Serotype clumps at Year 1:R | 0.0 |
| Serotype Missing/non-viable at Year 1:R | 0.0 |
| Serotype 3 at Year 2:R | 0.0 |
| Serotype 6C at Year 2:R | 0.9 |
| Serotype 7C at Year 2:R | 0.0 |
| Serotype 9N at Year 2:R | 0.0 |
| Serotype 10 at Year 2:R | 0.9 |
| Serotype 11 at Year 2:R | 2.7 |
| Serotype 12 at Year 2:R | 0.0 |
| Serotype 12F at Year 2:R | 0.0 |
| Serotype 13 at Year 2:R | 0.0 |
| Serotype 15A at Year 2:R | 0.9 |
| Serotype 15B at Year 2:R | 0.0 |
| Serotype 15C at Year 2:R | 1.8 |
| Serotype 15F at Year 2:R | 0.0 |
| Serotype 16 at Year 2:R | 0.0 |
| Serotype 17 at Year 2:R | 0.0 |
| Serotype 19A at Year 2:R | 6.3 |
| Serotype 19F at Year 2:R | 0.0 |
| Serotype 20 at Year 2:R | 0.0 |
| Serotype 21 at Year 2:R | 0.0 |
| Serotype 22F at Year 2:R | 0.0 |
| Serotype 23A at Year 2:R | 0.9 |
| Serotype 23B at Year 2:R | 0.9 |
| Serotype 31 at Year 2:R | 0.0 |
| Serotype 33A at Year 2:R | 0.0 |
| Serotype 33F at Year 2:R | 0.0 |
| Serotype 34 at Year 2:R | 0.0 |
| Serotype 35B at Year 2:R | 9.0 |
| Serotype 35F at Year 2:R | 0.0 |
| Serotype 38 at Year 2:R | 0.0 |
| Serotype clumps at Year 2:R | 0.0 |
| Serotype Missing/non-viable at Year 2:R | 0.0 |
| Serotype 3 at Year 3:R | 0.0 |
| Serotype 6C at Year 3:R | 0.0 |
| Serotype 7C at Year 3:R | 0.0 |
| Serotype 9N at Year 3:R | 0.0 |
| Serotype 10 at Year 3:R | 0.0 |
| Serotype 11 at Year 3:R | 1.8 |
| Serotype 12 at Year 3:R | 0.0 |
| Serotype 12F at Year 3:R | 0.0 |
| Serotype 13 at Year 3:R | 0.0 |
| Serotype 15A at Year 3:R | 0.0 |
| Serotype 15B at Year 3:R | 1.8 |
| Serotype 15C at Year 3:R | 0.9 |
| Serotype 15F at Year 3:R | 0.0 |
| Serotype 16 at Year 3:R | 0.9 |
| Serotype 17 at Year 3:R | 0.0 |
| Serotype 19A at Year 3:R | 6.3 |
| Serotype 19F at Year 3:R | 0.9 |
| Serotype 20 at Year 3:R | 0.0 |
| Serotype 21 at Year 3:R | 0.9 |
| Serotype 22F at Year 3:R | 0.0 |
| Serotype 23A at Year 3:R | 0.0 |
| Serotype 23B at Year 3:R | 2.7 |
| Serotype 31 at Year 3:R | 0.0 |
| Serotype 33A at Year 3:R | 0.0 |
| Serotype 33F at Year 3:R | 1.8 |
| Serotype 34 at Year 3:R | 0.0 |
| Serotype 35B at Year 3:R | 5.4 |
| Serotype 35F at Year 3:R | 0.9 |
| Serotype 38 at Year 3:R | 0.0 |
| Serotype clumps at Year 3:R | 0.0 |
| Serotype Missing/non-viable at Year 3:R | 0.9 |
Antimicrobial susceptibility of S pneumoniae isolates for penicillin from MEF samples were summarized by providing the range of MICs for penicillin tested and the percentage of the susceptibility interpretation was categorized as resistant, susceptible or intermediate for each serotype, and for each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19 A, 19 F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95 % CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | MEF Population |
|---|---|
| Serotype 3 at Year 1:S | 5.2 |
| Serotype 7C at Year 1:S | 1.5 |
| Serotype 9N at Year 1:S | 2.2 |
| Serotype 10 at Year 1:S | 3.0 |
| Serotype 11 at Year 1:S | 3.7 |
| Serotype 12 at Year 1:S | 0.0 |
| Serotype 12F at Year 1:S | 0.0 |
| Serotype 13 at Year 1:S | 0.0 |
| Serotype 15A at Year 1:S | 0.7 |
| Serotype 15B at Year 1:S | 3.7 |
| Serotype 15C at Year 1:S | 1.5 |
| Serotype 15F at Year 1:S | 0.0 |
| Serotype 16 at Year 1:S | 1.5 |
| Serotype 17 at Year 1:S | 0.0 |
| Serotype 19A at Year 1:S | 2.2 |
| Serotype 19F at Year 1:S | 0.7 |
| Serotype 20 at Year 1:S | 0.0 |
| Serotype 21 at Year 1:S | 3.0 |
| Serotype 22F at Year 1:S | 1.5 |
| Serotype 23A at Year 1:S | 0.0 |
| Serotype 23B at Year 1:S | 0.7 |
| Serotype 31 at Year 1:S | 2.2 |
| Serotype 33A at Year 1:S | 0.7 |
| Serotype 33F at Year 1:S | 1.5 |
| Serotype 34 at Year 1:S | 0.0 |
| Serotype 35B at Year 1:S | 0.0 |
| Serotype 35F at Year 1:S | 0.0 |
| Serotype 38 at Year 1:S | 0.7 |
| Serotype clumps at Year 1:S | 0.7 |
| Serotype Missing/non-viable at Year 1:S | 1.5 |
| Serotype 3 at Year 2:S | 6.3 |
| Serotype 6C at Year 2:S | 0.9 |
| Serotype 7C at Year 2:S | 0.0 |
| Serotype 9N at Year 2:S | 0.0 |
| Serotype 10 at Year 2:S | 0.9 |
| Serotype 11 at Year 2:S | 6.3 |
| Serotype 12 at Year 2:S | 0.0 |
| Serotype 12F at Year 2:S | 0.9 |
| Serotype 13 at Year 2:S | 0.0 |
| Serotype 15A at Year 2:S | 0.0 |
| Serotype 15B at Year 2:S | 1.8 |
| Serotype 15C at Year 2:S | 1.8 |
| Serotype 15F at Year 2:S | 0.0 |
| Serotype 16 at Year 2:S | 1.8 |
| Serotype 17 at Year 2:S | 0.9 |
| Serotype 19A at Year 2:S | 1.8 |
| Serotype 19F at Year 2:S | 0.9 |
| Serotype 20 at Year 2:S | 0.0 |
| Serotype 21 at Year 2:S | 8.1 |
| Serotype 22F at Year 2:S | 0.9 |
| Serotype 23A at Year 2:S | 0.0 |
| Serotype 23B at Year 2:S | 2.7 |
| Serotype 31 at Year 2:S | 1.8 |
| Serotype 33A at Year 2:S | 0.0 |
| Serotype 33F at Year 2:S | 0.0 |
| Serotype 34 at Year 2:S | 0.9 |
| Serotype 35B at Year 2:S | 0.9 |
| Serotype 35F at Year 2:S | 0.9 |
| Serotype 38 at Year 2:S | 0.9 |
| Serotype clumps at Year 2:S | 0.9 |
| Serotype Missing/non-viable at Year 2:S | 0.9 |
| Serotype 3 at Year 3:S | 6.3 |
| Serotype 6C at Year 3:S | 1.8 |
| Serotype 7C at Year 3:S | 0.0 |
| Serotype 9N at Year 3:S | 0.9 |
| Serotype 10 at Year 3:S | 2.7 |
| Serotype 11 at Year 3:S | 3.6 |
| Serotype 12 at Year 3:S | 0.0 |
| Serotype 12F at Year 3:S | 0.0 |
| Serotype 13 at Year 3:S | 0.0 |
| Serotype 15A at Year 3:S | 3.6 |
| Serotype 15B at Year 3:S | 1.8 |
| Serotype 15C at Year 3:S | 2.7 |
| Serotype 15F at Year 3:S | 0.0 |
| Serotype 16 at Year 3:S | 4.5 |
| Serotype 17 at Year 3:S | 0.9 |
| Serotype 19A at Year 3:S | 0.9 |
| Serotype 19F at Year 3:S | 3.6 |
| Serotype 20 at Year 3:S | 0.9 |
| Serotype 21 at Year 3:S | 5.4 |
| Serotype 22F at Year 3:S | 2.7 |
| Serotype 23A at Year 3:S | 0.9 |
| Serotype 23B at Year 3:S | 6.3 |
| Serotype 31 at Year 3:S | 3.6 |
| Serotype 33A at Year 3:S | 0.0 |
| Serotype 33F at Year 3:S | 0.9 |
| Serotype 34 at Year 3:S | 0.9 |
| Serotype 35B at Year 3:S | 0.0 |
| Serotype 35F at Year 3:S | 0.0 |
| Serotype 38 at Year 3:S | 0.9 |
| Serotype clumps at Year 3:S | 0.0 |
| Serotype Missing/non-viable at Year 3:S | 0.0 |
| Serotype 6C at Year 1:S | 2.2 |
| Serotype 3 at Year 1:I | 0.7 |
| Serotype 6C at Year 1:I | 3.7 |
| Serotype 7C at Year 1:I | 0.0 |
| Serotype 9N at Year 1:I | 0.0 |
| Serotype 10 at Year 1:I | 0.0 |
| Serotype 11 at Year 1:I | 0.0 |
| Serotype 12 at Year 1:I | 0.7 |
| Serotype 12F at Year 1:I | 0.0 |
| Serotype 13 at Year 1:I | 0.7 |
| Serotype 15A at Year 1:I | 3.0 |
| Serotype 15B at Year 1:I | 0.7 |
| Serotype 15C at Year 1:I | 2.2 |
| Serotype 15F at Year 1:I | 0.0 |
| Serotype 16 at Year 1:I | 0.0 |
| Serotype 17 at Year 1:I | 0.0 |
| Serotype 19A at Year 1:I | 2.2 |
| Serotype 19F at Year 1:I | 0.7 |
| Serotype 20 at Year 1:I | 0.0 |
| Serotype 21 at Year 1:I | 0.0 |
| Serotype 22F at Year 1:I | 0.0 |
| Serotype 23A at Year 1:I | 3.0 |
| Serotype 23B at Year 1:I | 0.7 |
| Serotype 31 at Year 1:I | 0.0 |
| Serotype 33A at Year 1:I | 0.0 |
| Serotype 33F at Year 1:I | 1.5 |
| Serotype 34 at Year 1:I | 0.0 |
| Serotype 35B at Year 1:I | 5.2 |
| Serotype 35F at Year 1:I | 0.0 |
| Serotype 38 at Year 1:I | 0.0 |
| Serotype clumps at Year 1:I | 0.0 |
| Serotype Missing/non-viable at Year 1:I | 0.0 |
| Serotype 3 at Year 2:I | 0.0 |
| Serotype 6C at Year 2:I | 2.7 |
| Serotype 7C at Year 2:I | 0.0 |
| Serotype 9N at Year 2:I | 0.0 |
| Serotype 10 at Year 2:I | 0.0 |
| Serotype 11 at Year 2:I | 0.0 |
| Serotype 12 at Year 2:I | 0.0 |
| Serotype 12F at Year 2:I | 0.0 |
| Serotype 13 at Year 2:I | 0.0 |
| Serotype 15A at Year 2:I | 0.9 |
| Serotype 15B at Year 2:I | 2.7 |
| Serotype 15C at Year 2:I | 0.9 |
| Serotype 15F at Year 2:I | 0.0 |
| Serotype 16 at Year 2:I | 0.9 |
| Serotype 17 at Year 2:I | 0.9 |
| Serotype 19A at Year 2:I | 1.8 |
| Serotype 19F at Year 2:I | 0.0 |
| Serotype 20 at Year 2:I | 0.0 |
| Serotype 21 at Year 2:I | 0.9 |
| Serotype 22F at Year 2:I | 0.0 |
| Serotype 23A at Year 2:I | 4.5 |
| Serotype 23B at Year 2:I | 3.6 |
| Serotype 31 at Year 2:I | 0.0 |
| Serotype 33A at Year 2:I | 0.0 |
| Serotype 33F at Year 2:I | 0.0 |
| Serotype 34 at Year 2:I | 0.0 |
| Serotype 35B at Year 2:I | 9.9 |
| Serotype 35F at Year 2:I | 0.0 |
| Serotype 38 at Year 2:I | 0.0 |
| Serotype clumps at Year 2:I | 0.0 |
| Serotype Missing/non-viable at Year 2:I | 0.0 |
| Serotype 3 at Year 3:I | 0.0 |
| Serotype 6C at Year 3:I | 0.0 |
| Serotype 7C at Year 3:I | 0.0 |
| Serotype 9N at Year 3:I | 0.0 |
| Serotype 10 at Year 3:I | 0.0 |
| Serotype 11 at Year 3:I | 0.0 |
| Serotype 12 at Year 3:I | 0.0 |
| Serotype 12F at Year 3:I | 0.0 |
| Serotype 13 at Year 3:I | 0.0 |
| Serotype 15A at Year 3:I | 1.8 |
| Serotype 15B at Year 3:I | 2.7 |
| Serotype 15C at Year 3:I | 2.7 |
| Serotype 15F at Year 3:I | 0.9 |
| Serotype 16 at Year 3:I | 0.0 |
| Serotype 17 at Year 3:I | 0.0 |
| Serotype 19A at Year 3:I | 0.0 |
| Serotype 19F at Year 3:I | 0.0 |
| Serotype 20 at Year 3:I | 0.0 |
| Serotype 21 at Year 3:I | 0.0 |
| Serotype 22F at Year 3:I | 0.0 |
| Serotype 23A at Year 3:I | 1.8 |
| Serotype 23B at Year 3:I | 1.8 |
| Serotype 31 at Year 3:I | 0.9 |
| Serotype 33A at Year 3:I | 0.0 |
| Serotype 33F at Year 3:I | 0.9 |
| Serotype 34 at Year 3:I | 0.0 |
| Serotype 35B at Year 3:I | 6.3 |
| Serotype 35F at Year 3:I | 0.9 |
| Serotype 38 at Year 3:I | 0.0 |
| Serotype clumps at Year 3:I | 0.0 |
| Serotype Missing/non-viable at Year 3:I | 1.8 |
| Serotype 3 at Year 1:R | 0.0 |
| Serotype 6C at Year 1:R | 0.7 |
| Serotype 7C at Year 1:R | 0.0 |
| Serotype 9N at Year 1:R | 0.0 |
| Serotype 10 at Year 1:R | 0.0 |
| Serotype 11 at Year 1:R | 0.0 |
| Serotype 12 at Year 1:R | 0.0 |
| Serotype 12F at Year 1:R | 0.0 |
| Serotype 13 at Year 1:R | 0.0 |
| Serotype 15A at Year 1:R | 0.0 |
| Serotype 15B at Year 1:R | 0.0 |
| Serotype 15C at Year 1:R | 0.0 |
| Serotype 15F at Year 1:R | 0.0 |
| Serotype 16 at Year 1:R | 0.0 |
| Serotype 17 at Year 1:R | 0.0 |
| Serotype 19A at Year 1:R | 25.9 |
| Serotype 19F at Year 1:R | 0.7 |
| Serotype 20 at Year 1:R | 0.0 |
| Serotype 21 at Year 1:R | 0.0 |
| Serotype 22F at Year 1:R | 0.0 |
| Serotype 23A at Year 1:R | 0.0 |
| Serotype 23B at Year 1:R | 0.0 |
| Serotype 31 at Year 1:R | 0.0 |
| Serotype 33A at Year 1:R | 0.0 |
| Serotype 33F at Year 1:R | 0.0 |
| Serotype 34 at Year 1:R | 0.0 |
| Serotype 35B at Year 1:R | 1.5 |
| Serotype 35F at Year 1:R | 0.0 |
| Serotype 38 at Year 1:R | 0.0 |
| Serotype clumps at Year 1:R | 0.7 |
| Serotype Missing/non-viable at Year 1:R | 0.0 |
| Serotype 3 at Year 2:R | 0.0 |
| Serotype 6C at Year 2:R | 0.0 |
| Serotype 7C at Year 2:R | 0.0 |
| Serotype 9N at Year 2:R | 0.0 |
| Serotype 10 at Year 2:R | 0.0 |
| Serotype 11 at Year 2:R | 0.9 |
| Serotype 12 at Year 2:R | 0.0 |
| Serotype 12F at Year 2:R | 0.0 |
| Serotype 13 at Year 2:R | 0.0 |
| Serotype 15A at Year 2:R | 0.0 |
| Serotype 15B at Year 2:R | 0.0 |
| Serotype 15C at Year 2:R | 0.0 |
| Serotype 15F at Year 2:R | 0.0 |
| Serotype 16 at Year 2:R | 0.0 |
| Serotype 17 at Year 2:R | 0.0 |
| Serotype 19A at Year 2:R | 18.9 |
| Serotype 19F at Year 2:R | 0.0 |
| Serotype 20 at Year 2:R | 0.0 |
| Serotype 21 at Year 2:R | 0.0 |
| Serotype 22F at Year 2:R | 0.0 |
| Serotype 23A at Year 2:R | 0.0 |
| Serotype 23B at Year 2:R | 0.9 |
| Serotype 31 at Year 2:R | 0.0 |
| Serotype 33A at Year 2:R | 0.0 |
| Serotype 33F at Year 2:R | 0.0 |
| Serotype 34 at Year 2:R | 0.0 |
| Serotype 35B at Year 2:R | 1.8 |
| Serotype 35F at Year 2:R | 0.0 |
| Serotype 38 at Year 2:R | 0.0 |
| Serotype clumps at Year 2:R | 0.0 |
| Serotype Missing/non-viable at Year 2:R | 0.0 |
| Serotype 3 at Year 3:R | 0.9 |
| Serotype 6C at Year 3:R | 0.0 |
| Serotype 7C at Year 3:R | 0.0 |
| Serotype 9N at Year 3:R | 0.0 |
| Serotype 10 at Year 3:R | 0.0 |
| Serotype 11 at Year 3:R | 0.0 |
| Serotype 12 at Year 3:R | 0.0 |
| Serotype 12F at Year 3:R | 0.0 |
| Serotype 13 at Year 3:R | 0.0 |
| Serotype 15A at Year 3:R | 0.9 |
| Serotype 15B at Year 3:R | 0.0 |
| Serotype 15C at Year 3:R | 0.0 |
| Serotype 15F at Year 3:R | 0.0 |
| Serotype 16 at Year 3:R | 0.0 |
| Serotype 17 at Year 3:R | 0.0 |
| Serotype 19A at Year 3:R | 9.0 |
| Serotype 19F at Year 3:R | 1.8 |
| Serotype 20 at Year 3:R | 0.0 |
| Serotype 21 at Year 3:R | 0.0 |
| Serotype 22F at Year 3:R | 0.0 |
| Serotype 23A at Year 3:R | 0.0 |
| Serotype 23B at Year 3:R | 0.0 |
| Serotype 31 at Year 3:R | 0.0 |
| Serotype 33A at Year 3:R | 0.0 |
| Serotype 33F at Year 3:R | 0.0 |
| Serotype 34 at Year 3:R | 0.0 |
| Serotype 35B at Year 3:R | 2.7 |
| Serotype 35F at Year 3:R | 0.0 |
| Serotype 38 at Year 3:R | 0.0 |
| Serotype clumps at Year 3:R | 0.0 |
| Serotype Missing/non-viable at Year 3:R | 0.0 |
Antimicrobial susceptibility of S pneumoniae isolates for TMP/S from MEF samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 6C, 7C, 9N, 10, 11, 12, 12F, 13, 15A, 15B, 15C, 15F, 16, 17, 19A, 19F, 20, 21, 22F, 23A, 23B, 31, 33A, 33F, 34, 35B, 35F, 38, clumps and missing or non-viable, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. Missing or non-viable included isolates that were either not sent from an external laboratory, were non-viable or lost on culture prior to sending, or were non-viable on receipt in the central laboratory.'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | MEF Population |
|---|---|
| Serotype 3 at Year 1:S | 3.0 |
| Serotype 6C at Year 1:S | 0.7 |
| Serotype 7C at Year 1:S | 1.5 |
| Serotype 9N at Year 1:S | 1.5 |
| Serotype 10 at Year 1:S | 0.7 |
| Serotype 11 at Year 1:S | 2.2 |
| Serotype 12 at Year 1:S | 0.0 |
| Serotype 12F at Year 1:S | 0.0 |
| Serotype 13 at Year 1:S | 0.7 |
| Serotype 15A at Year 1:S | 0.0 |
| Serotype 15B at Year 1:S | 1.5 |
| Serotype 15C at Year 1:S | 0.0 |
| Serotype 15F at Year 1:S | 0.0 |
| Serotype 16 at Year 1:S | 1.5 |
| Serotype 17 at Year 1:S | 0.0 |
| Serotype 19A at Year 1:S | 0.7 |
| Serotype 19F at Year 1:S | 0.7 |
| Serotype 20 at Year 1:S | 0.0 |
| Serotype 21 at Year 1:S | 1.5 |
| Serotype 22F at Year 1:S | 0.7 |
| Serotype 23A at Year 1:S | 0.7 |
| Serotype 23B at Year 1:S | 0.0 |
| Serotype 31 at Year 1:S | 0.7 |
| Serotype 33A at Year 1:S | 0.0 |
| Serotype 33F at Year 1:S | 0.7 |
| Serotype 34 at Year 1:S | 0.0 |
| Serotype 35B at Year 1:S | 0.7 |
| Serotype 35F at Year 1:S | 0.0 |
| Serotype 38 at Year 1:S | 0.7 |
| Serotype clumps at Year 1:S | 0.7 |
| Serotype Missing/non-viable at Year 1:S | 0.7 |
| Serotype 3 at Year 2:S | 1.8 |
| Serotype 6C at Year 2:S | 0.9 |
| Serotype 7C at Year 2:S | 0.0 |
| Serotype 9N at Year 2:S | 0.0 |
| Serotype 10 at Year 2:S | 0.0 |
| Serotype 11 at Year 2:S | 3.6 |
| Serotype 12 at Year 2:S | 0.0 |
| Serotype 12F at Year 2:S | 0.0 |
| Serotype 13 at Year 2:S | 0.0 |
| Serotype 15A at Year 2:S | 0.0 |
| Serotype 15B at Year 2:S | 1.8 |
| Serotype 15C at Year 2:S | 0.0 |
| Serotype 15F at Year 2:S | 0.0 |
| Serotype 16 at Year 2:S | 0.9 |
| Serotype 17 at Year 2:S | 0.0 |
| Serotype 19A at Year 2:S | 1.8 |
| Serotype 19F at Year 2:S | 0.0 |
| Serotype 20 at Year 2:S | 0.0 |
| Serotype 21 at Year 2:S | 3.6 |
| Serotype 22F at Year 2:S | 0.9 |
| Serotype 23A at Year 2:S | 0.9 |
| Serotype 23B at Year 2:S | 0.9 |
| Serotype 31 at Year 2:S | 0.0 |
| Serotype 33A at Year 2:S | 0.0 |
| Serotype 33F at Year 2:S | 0.0 |
| Serotype 34 at Year 2:S | 0.0 |
| Serotype 35B at Year 2:S | 2.7 |
| Serotype 35F at Year 2:S | 0.0 |
| Serotype 38 at Year 2:S | 0.0 |
| Serotype clumps at Year 2:S | 0.9 |
| Serotype Missing/non-viable at Year 2:S | 0.0 |
| Serotype 3 at Year 3:S | 2.7 |
| Serotype 6C at Year 3:S | 1.8 |
| Serotype 7C at Year 3:S | 0.0 |
| Serotype 9N at Year 3:S | 0.0 |
| Serotype 10 at Year 3:S | 0.0 |
| Serotype 11 at Year 3:S | 0.9 |
| Serotype 12 at Year 3:S | 0.0 |
| Serotype 12F at Year 3:S | 0.0 |
| Serotype 13 at Year 3:S | 0.0 |
| Serotype 15A at Year 3:S | 1.8 |
| Serotype 15B at Year 3:S | 0.0 |
| Serotype 15C at Year 3:S | 2.7 |
| Serotype 15F at Year 3:S | 0.0 |
| Serotype 16 at Year 3:S | 0.9 |
| Serotype 17 at Year 3:S | 0.0 |
| Serotype 19A at Year 3:S | 0.9 |
| Serotype 19F at Year 3:S | 0.9 |
| Serotype 20 at Year 3:S | 0.0 |
| Serotype 21 at Year 3:S | 3.6 |
| Serotype 22F at Year 3:S | 2.7 |
| Serotype 23A at Year 3:S | 0.0 |
| Serotype 23B at Year 3:S | 1.8 |
| Serotype 31 at Year 3:S | 1.8 |
| Serotype 33A at Year 3:S | 0.0 |
| Serotype 33F at Year 3:S | 0.0 |
| Serotype 34 at Year 3:S | 0.0 |
| Serotype 35B at Year 3:S | 0.9 |
| Serotype 35F at Year 3:S | 0.9 |
| Serotype 38 at Year 3:S | 0.0 |
| Serotype clumps at Year 3:S | 0.0 |
| Serotype Missing/non-viable at Year 3:S | 0.0 |
| Serotype 3 at Year 1:I | 0.0 |
| Serotype 6C at Year 1:I | 1.5 |
| Serotype 7C at Year 1:I | 0.0 |
| Serotype 9N at Year 1:I | 0.0 |
| Serotype 10 at Year 1:I | 0.0 |
| Serotype 11 at Year 1:I | 0.0 |
| Serotype 12 at Year 1:I | 0.0 |
| Serotype 12F at Year 1:I | 0.0 |
| Serotype 13 at Year 1:I | 0.0 |
| Serotype 15A at Year 1:I | 0.0 |
| Serotype 15B at Year 1:I | 0.0 |
| Serotype 15C at Year 1:I | 0.7 |
| Serotype 15F at Year 1:I | 0.0 |
| Serotype 16 at Year 1:I | 0.0 |
| Serotype 17 at Year 1:I | 0.0 |
| Serotype 19A at Year 1:I | 14.1 |
| Serotype 19F at Year 1:I | 0.7 |
| Serotype 20 at Year 1:I | 0.0 |
| Serotype 21 at Year 1:I | 0.0 |
| Serotype 22F at Year 1:I | 0.7 |
| Serotype 23A at Year 1:I | 0.0 |
| Serotype 23B at Year 1:I | 0.0 |
| Serotype 31 at Year 1:I | 0.0 |
| Serotype 33A at Year 1:I | 0.0 |
| Serotype 33F at Year 1:I | 0.0 |
| Serotype 34 at Year 1:I | 0.0 |
| Serotype 35B at Year 1:I | 0.0 |
| Serotype 35F at Year 1:I | 0.0 |
| Serotype 38 at Year 1:I | 0.0 |
| Serotype clumps at Year 1:I | 0.0 |
| Serotype Missing/non-viable at Year 1:I | 0.0 |
| Serotype 3 at Year 2:I | 0.0 |
| Serotype 6C at Year 2:I | 0.0 |
| Serotype 7C at Year 2:I | 0.0 |
| Serotype 9N at Year 2:I | 0.0 |
| Serotype 10 at Year 2:I | 0.0 |
| Serotype 11 at Year 2:I | 0.9 |
| Serotype 12 at Year 2:I | 0.0 |
| Serotype 12F at Year 2:I | 0.0 |
| Serotype 13 at Year 2:I | 0.0 |
| Serotype 15A at Year 2:I | 0.0 |
| Serotype 15B at Year 2:I | 1.8 |
| Serotype 15C at Year 2:I | 0.0 |
| Serotype 15F at Year 2:I | 0.0 |
| Serotype 16 at Year 2:I | 0.0 |
| Serotype 17 at Year 2:I | 0.0 |
| Serotype 19A at Year 2:I | 12.6 |
| Serotype 19F at Year 2:I | 0.0 |
| Serotype 20 at Year 2:I | 0.0 |
| Serotype 21 at Year 2:I | 0.0 |
| Serotype 22F at Year 2:I | 0.0 |
| Serotype 23A at Year 2:I | 0.0 |
| Serotype 23B at Year 2:I | 0.9 |
| Serotype 31 at Year 2:I | 0.0 |
| Serotype 33A at Year 2:I | 0.0 |
| Serotype 33F at Year 2:I | 0.0 |
| Serotype 34 at Year 2:I | 0.0 |
| Serotype 35B at Year 2:I | 0.0 |
| Serotype 35F at Year 2:I | 0.0 |
| Serotype 38 at Year 2:I | 0.0 |
| Serotype clumps at Year 2:I | 0.0 |
| Serotype Missing/non-viable at Year 2:I | 0.0 |
| Serotype 3 at Year 3:I | 0.9 |
| Serotype 6C at Year 3:I | 0.0 |
| Serotype 7C at Year 3:I | 0.0 |
| Serotype 9N at Year 3:I | 0.0 |
| Serotype 10 at Year 3:I | 0.0 |
| Serotype 11 at Year 3:I | 0.9 |
| Serotype 12 at Year 3:I | 0.0 |
| Serotype 12F at Year 3:I | 0.0 |
| Serotype 13 at Year 3:I | 0.0 |
| Serotype 15A at Year 3:I | 1.8 |
| Serotype 15B at Year 3:I | 0.9 |
| Serotype 15C at Year 3:I | 0.9 |
| Serotype 15F at Year 3:I | 0.9 |
| Serotype 16 at Year 3:I | 0.0 |
| Serotype 17 at Year 3:I | 0.0 |
| Serotype 19A at Year 3:I | 2.7 |
| Serotype 19F at Year 3:I | 2.7 |
| Serotype 20 at Year 3:I | 0.0 |
| Serotype 21 at Year 3:I | 0.0 |
| Serotype 22F at Year 3:I | 0.0 |
| Serotype 23A at Year 3:I | 0.0 |
| Serotype 23B at Year 3:I | 0.0 |
| Serotype 31 at Year 3:I | 0.0 |
| Serotype 33A at Year 3:I | 0.0 |
| Serotype 33F at Year 3:I | 0.0 |
| Serotype 34 at Year 3:I | 0.9 |
| Serotype 35B at Year 3:I | 0.9 |
| Serotype 35F at Year 3:I | 0.0 |
| Serotype 38 at Year 3:I | 0.0 |
| Serotype clumps at Year 3:I | 0.0 |
| Serotype Missing/non-viable at Year 3:I | 0.0 |
| Serotype 3 at Year 1:R | 3.0 |
| Serotype 6C at Year 1:R | 4.4 |
| Serotype 7C at Year 1:R | 0.0 |
| Serotype 9N at Year 1:R | 0.7 |
| Serotype 10 at Year 1:R | 1.5 |
| Serotype 11 at Year 1:R | 1.5 |
| Serotype 12 at Year 1:R | 0.7 |
| Serotype 12F at Year 1:R | 0.0 |
| Serotype 13 at Year 1:R | 0.0 |
| Serotype 15A at Year 1:R | 3.7 |
| Serotype 15B at Year 1:R | 2.2 |
| Serotype 15C at Year 1:R | 3.0 |
| Serotype 15F at Year 1:R | 0.0 |
| Serotype 16 at Year 1:R | 0.0 |
| Serotype 17 at Year 1:R | 0.0 |
| Serotype 19A at Year 1:R | 15.6 |
| Serotype 19F at Year 1:R | 0.7 |
| Serotype 20 at Year 1:R | 0.0 |
| Serotype 21 at Year 1:R | 1.5 |
| Serotype 22F at Year 1:R | 0.0 |
| Serotype 23A at Year 1:R | 2.2 |
| Serotype 23B at Year 1:R | 0.7 |
| Serotype 31 at Year 1:R | 1.5 |
| Serotype 33A at Year 1:R | 0.7 |
| Serotype 33F at Year 1:R | 2.2 |
| Serotype 34 at Year 1:R | 0.0 |
| Serotype 35B at Year 1:R | 5.9 |
| Serotype 35F at Year 1:R | 0.0 |
| Serotype 38 at Year 1:R | 0.0 |
| Serotype clumps at Year 1:R | 0.0 |
| Serotype Missing/non-viable at Year 1:R | 0.0 |
| Serotype 3 at Year 2:R | 4.5 |
| Serotype 6C at Year 2:R | 2.7 |
| Serotype 7C at Year 2:R | 0.0 |
| Serotype 9N at Year 2:R | 0.0 |
| Serotype 10 at Year 2:R | 0.9 |
| Serotype 11 at Year 2:R | 2.7 |
| Serotype 12 at Year 2:R | 0.0 |
| Serotype 12F at Year 2:R | 0.9 |
| Serotype 13 at Year 2:R | 0.0 |
| Serotype 15A at Year 2:R | 0.9 |
| Serotype 15B at Year 2:R | 0.9 |
| Serotype 15C at Year 2:R | 2.7 |
| Serotype 15F at Year 2:R | 0.0 |
| Serotype 16 at Year 2:R | 1.8 |
| Serotype 17 at Year 2:R | 1.8 |
| Serotype 19A at Year 2:R | 8.1 |
| Serotype 19F at Year 2:R | 0.9 |
| Serotype 20 at Year 2:R | 0.0 |
| Serotype 21 at Year 2:R | 4.5 |
| Serotype 22F at Year 2:R | 0.0 |
| Serotype 23A at Year 2:R | 3.6 |
| Serotype 23B at Year 2:R | 5.4 |
| Serotype 31 at Year 2:R | 1.8 |
| Serotype 33A at Year 2:R | 0.0 |
| Serotype 33F at Year 2:R | 0.0 |
| Serotype 34 at Year 2:R | 0.9 |
| Serotype 35B at Year 2:R | 9.9 |
| Serotype 35F at Year 2:R | 0.9 |
| Serotype 38 at Year 2:R | 0.9 |
| Serotype clumps at Year 2:R | 0.0 |
| Serotype Missing/non-viable at Year 2:R | 0.9 |
| Serotype 3 at Year 3:R | 3.6 |
| Serotype 6C at Year 3:R | 0.0 |
| Serotype 7C at Year 3:R | 0.0 |
| Serotype 9N at Year 3:R | 0.9 |
| Serotype 10 at Year 3:R | 2.7 |
| Serotype 11 at Year 3:R | 1.8 |
| Serotype 12 at Year 3:R | 0.0 |
| Serotype 12F at Year 3:R | 0.0 |
| Serotype 13 at Year 3:R | 0.0 |
| Serotype 15A at Year 3:R | 2.7 |
| Serotype 15B at Year 3:R | 3.6 |
| Serotype 15C at Year 3:R | 1.8 |
| Serotype 15F at Year 3:R | 0.0 |
| Serotype 16 at Year 3:R | 3.6 |
| Serotype 17 at Year 3:R | 0.9 |
| Serotype 19A at Year 3:R | 6.3 |
| Serotype 19F at Year 3:R | 1.8 |
| Serotype 20 at Year 3:R | 0.9 |
| Serotype 21 at Year 3:R | 1.8 |
| Serotype 22F at Year 3:R | 0.0 |
| Serotype 23A at Year 3:R | 2.7 |
| Serotype 23B at Year 3:R | 6.3 |
| Serotype 31 at Year 3:R | 2.7 |
| Serotype 33A at Year 3:R | 0.0 |
| Serotype 33F at Year 3:R | 1.8 |
| Serotype 34 at Year 3:R | 0.0 |
| Serotype 35B at Year 3:R | 9.0 |
| Serotype 35F at Year 3:R | 0.9 |
| Serotype 38 at Year 3:R | 0.9 |
| Serotype clumps at Year 3:R | 0.0 |
| Serotype Missing/non-viable at Year 3:R | 1.8 |
Antimicrobial susceptibility of S pneumoniae isolates for ceftriaxone from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | Mastoid Population |
|---|---|
| Serotype 3 at Year 1:S | 0.0 |
| Serotype 12 at Year 1:S | 5.6 |
| Serotype 15A at Year 1:S | 5.6 |
| Serotype 15B at Year 1:S | 5.6 |
| Serotype 15F at Year 1:S | 0.0 |
| Serotype 19A at Year 1:S | 27.8 |
| Serotype 19F at Year 1:S | 11.1 |
| Serotype 21 at Year 1:S | 0.0 |
| Serotype 22F at Year 1:S | 11.1 |
| Serotype 23A at Year 1:S | 5.6 |
| Serotype 38 at Year 1:S | 5.6 |
| Serotype 3 at Year 2:S | 28.6 |
| Serotype 12 at Year 2:S | 0.0 |
| Serotype 15A at Year 2:S | 0.0 |
| Serotype 15B at Year 2:S | 0.0 |
| Serotype 15F at Year 2:S | 0.0 |
| Serotype 19A at Year 2:S | 57.1 |
| Serotype 19F at Year 2:S | 0.0 |
| Serotype 21 at Year 2:S | 0.0 |
| Serotype 22F at Year 2:S | 0.0 |
| Serotype 23A at Year 2:S | 0.0 |
| Serotype 38 at Year 2:S | 0.0 |
| Serotype 3 at Year 3:S | 44.4 |
| Serotype 12 at Year 3:S | 0.0 |
| Serotype 15A at Year 3:S | 0.0 |
| Serotype 15B at Year 3:S | 0.0 |
| Serotype 15F at Year 3:S | 0.0 |
| Serotype 19A at Year 3:S | 0.0 |
| Serotype 19F at Year 3:S | 11.1 |
| Serotype 21 at Year 3:S | 0.0 |
| Serotype 22F at Year 3:S | 0.0 |
| Serotype 23A at Year 3:S | 0.0 |
| Serotype 38 at Year 3:S | 0.0 |
| Serotype 3 at Year 1:I | 0.0 |
| Serotype 12 at Year 1:I | 0.0 |
| Serotype 15A at Year 1:I | 0.0 |
| Serotype 15B at Year 1:I | 0.0 |
| Serotype 15F at Year 1:I | 0.0 |
| Serotype 19A at Year 1:I | 0.0 |
| Serotype 19F at Year 1:I | 0.0 |
| Serotype 21 at Year 1:I | 0.0 |
| Serotype 22F at Year 1:I | 0.0 |
| Serotype 23A at Year 1:I | 0.0 |
| Serotype 38 at Year 1:I | 0.0 |
| Serotype 3 at Year 2:I | 0.0 |
| Serotype 12 at Year 2:I | 0.0 |
| Serotype 15A at Year 2:I | 0.0 |
| Serotype 15B at Year 2:I | 0.0 |
| Serotype 15F at Year 2:I | 0.0 |
| Serotype 19A at Year 2:I | 0.0 |
| Serotype 19F at Year 2:I | 0.0 |
| Serotype 21 at Year 2:I | 0.0 |
| Serotype 22F at Year 2:I | 0.0 |
| Serotype 23A at Year 2:I | 0.0 |
| Serotype 38 at Year 2:I | 0.0 |
| Serotype 3 at Year 3:I | 0.0 |
| Serotype 12 at Year 3:I | 0.0 |
| Serotype 15A at Year 3:I | 0.0 |
| Serotype 15B at Year 3:I | 0.0 |
| Serotype 15F at Year 3:I | 0.0 |
| Serotype 19A at Year 3:I | 0.0 |
| Serotype 19F at Year 3:I | 0.0 |
| Serotype 21 at Year 3:I | 0.0 |
| Serotype 22F at Year 3:I | 0.0 |
| Serotype 23A at Year 3:I | 0.0 |
| Serotype 38 at Year 3:I | 0.0 |
| Serotype 3 at Year 1:R | 0.0 |
| Serotype 12 at Year 1:R | 0.0 |
| Serotype 15A at Year 1:R | 0.0 |
| Serotype 15B at Year 1:R | 0.0 |
| Serotype 15F at Year 1:R | 0.0 |
| Serotype 19A at Year 1:R | 5.6 |
| Serotype 19F at Year 1:R | 0.0 |
| Serotype 21 at Year 1:R | 0.0 |
| Serotype 22F at Year 1:R | 0.0 |
| Serotype 23A at Year 1:R | 0.0 |
| Serotype 38 at Year 1:R | 0.0 |
| Serotype 3 at Year 2:R | 0.0 |
| Serotype 12 at Year 2:R | 0.0 |
| Serotype 15A at Year 2:R | 0.0 |
| Serotype 15B at Year 2:R | 0.0 |
| Serotype 15F at Year 2:R | 0.0 |
| Serotype 19A at Year 2:R | 0.0 |
| Serotype 19F at Year 2:R | 0.0 |
| Serotype 21 at Year 2:R | 0.0 |
| Serotype 22F at Year 2:R | 0.0 |
| Serotype 23A at Year 2:R | 0.0 |
| Serotype 38 at Year 2:R | 0.0 |
| Serotype 3 at Year 3:R | 0.0 |
| Serotype 12 at Year 3:R | 0.0 |
| Serotype 15A at Year 3:R | 0.0 |
| Serotype 15B at Year 3:R | 0.0 |
| Serotype 15F at Year 3:R | 0.0 |
| Serotype 19A at Year 3:R | 11.1 |
| Serotype 19F at Year 3:R | 0.0 |
| Serotype 21 at Year 3:R | 0.0 |
| Serotype 22F at Year 3:R | 0.0 |
| Serotype 23A at Year 3:R | 0.0 |
| Serotype 38 at Year 3:R | 0.0 |
Antimicrobial susceptibility of S pneumoniae isolates for clindamycin from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | Mastoid Population |
|---|---|
| Serotype 3 at Year 1:S | 0.0 |
| Serotype 15F at Year 1:S | 0.0 |
| Serotype 19A at Year 1:S | 5.6 |
| Serotype 19F at Year 1:S | 0.0 |
| Serotype 21 at Year 1:S | 0.0 |
| Serotype 22F at Year 1:S | 5.6 |
| Serotype 23A at Year 1:S | 5.6 |
| Serotype 38 at Year 1:S | 5.6 |
| Serotype 3 at Year 2:S | 28.6 |
| Serotype 12 at Year 2:S | 0.0 |
| Serotype 15A at Year 2:S | 0.0 |
| Serotype 15B at Year 2:S | 0.0 |
| Serotype 15F at Year 2:S | 0.0 |
| Serotype 19A at Year 2:S | 28.6 |
| Serotype 19F at Year 2:S | 0.0 |
| Serotype 21 at Year 2:S | 0.0 |
| Serotype 22F at Year 2:S | 0.0 |
| Serotype 23A at Year 2:S | 0.0 |
| Serotype 38 at Year 2:S | 0.0 |
| Serotype 3 at Year 3:S | 22.2 |
| Serotype 12 at Year 3:S | 0.0 |
| Serotype 15A at Year 3:S | 0.0 |
| Serotype 15B at Year 3:S | 0.0 |
| Serotype 15F at Year 3:S | 0.0 |
| Serotype 19A at Year 3:S | 0.0 |
| Serotype 19F at Year 3:S | 11.1 |
| Serotype 21 at Year 3:S | 0.0 |
| Serotype 22F at Year 3:S | 0.0 |
| Serotype 23A at Year 3:S | 0.0 |
| Serotype 38 at Year 3:S | 0.0 |
| Serotype 3 at Year 1:I | 0.0 |
| Serotype 12 at Year 1:I | 0.0 |
| Serotype 15A at Year 1:I | 0.0 |
| Serotype 15B at Year 1:I | 0.0 |
| Serotype 15F at Year 1:I | 0.0 |
| Serotype 19A at Year 1:I | 5.6 |
| Serotype 19F at Year 1:I | 0.0 |
| Serotype 21 at Year 1:I | 0.0 |
| Serotype 22F at Year 1:I | 0.0 |
| Serotype 23A at Year 1:I | 0.0 |
| Serotype 38 at Year 1:I | 0.0 |
| Serotype 3 at Year 2:I | 0.0 |
| Serotype 12 at Year 2:I | 0.0 |
| Serotype 15A at Year 2:I | 0.0 |
| Serotype 15B at Year 2:I | 0.0 |
| Serotype 15F at Year 2:I | 0.0 |
| Serotype 19A at Year 2:I | 14.3 |
| Serotype 19F at Year 2:I | 0.0 |
| Serotype 21 at Year 2:I | 0.0 |
| Serotype 22F at Year 2:I | 0.0 |
| Serotype 23A at Year 2:I | 0.0 |
| Serotype 38 at Year 2:I | 0.0 |
| Serotype 3 at Year 3:I | 0.0 |
| Serotype 12 at Year 3:I | 0.0 |
| Serotype 15A at Year 3:I | 0.0 |
| Serotype 15B at Year 3:I | 0.0 |
| Serotype 15F at Year 3:I | 0.0 |
| Serotype 19A at Year 3:I | 0.0 |
| Serotype 19F at Year 3:I | 0.0 |
| Serotype 21 at Year 3:I | 0.0 |
| Serotype 22F at Year 3:I | 0.0 |
| Serotype 23A at Year 3:I | 0.0 |
| Serotype 38 at Year 3:I | 0.0 |
| Serotype 3 at Year 1:R | 0.0 |
| Serotype 12 at Year 1:R | 0.0 |
| Serotype 15A at Year 1:R | 5.6 |
| Serotype 15B at Year 1:R | 0.0 |
| Serotype 15F at Year 1:R | 0.0 |
| Serotype 19A at Year 1:R | 22.2 |
| Serotype 19F at Year 1:R | 5.6 |
| Serotype 21 at Year 1:R | 0.0 |
| Serotype 22F at Year 1:R | 0.0 |
| Serotype 23A at Year 1:R | 0.0 |
| Serotype 38 at Year 1:R | 0.0 |
| Serotype 3 at Year 2:R | 0.0 |
| Serotype 12 at Year 2:R | 0.0 |
| Serotype 15A at Year 2:R | 0.0 |
| Serotype 15B at Year 2:R | 0.0 |
| Serotype 15F at Year 2:R | 0.0 |
| Serotype 19A at Year 2:R | 28.6 |
| Serotype 19F at Year 2:R | 0.0 |
| Serotype 21 at Year 2:R | 0.0 |
| Serotype 22F at Year 2:R | 0.0 |
| Serotype 23A at Year 2:R | 0.0 |
| Serotype 38 at Year 2:R | 0.0 |
| Serotype 3 at Year 3:R | 11.1 |
| Serotype 12 at Year 3:R | 0.0 |
| Serotype 15A at Year 3:R | 0.0 |
| Serotype 15B at Year 3:R | 0.0 |
| Serotype 15F at Year 3:R | 0.0 |
| Serotype 19A at Year 3:R | 11.1 |
| Serotype 19F at Year 3:R | 0.0 |
| Serotype 21 at Year 3:R | 0.0 |
| Serotype 22F at Year 3:R | 0.0 |
| Serotype 23A at Year 3:R | 0.0 |
| Serotype 38 at Year 3:R | 0.0 |
| Serotype 12 at Year 1:S | 5.6 |
| Serotype 15A at Year 1:S | 0.0 |
| Serotype 15B at Year 1:S | 5.6 |
Antimicrobial susceptibility of S pneumoniae isolates for erythromycin from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | Mastoid Population |
|---|---|
| Serotype 3 at Year 1:S | 0.0 |
| Serotype 12 at Year 1:S | 5.6 |
| Serotype 15A at Year 1:S | 0.0 |
| Serotype 15B at Year 1:S | 5.6 |
| Serotype 15F at Year 1:S | 0.0 |
| Serotype 19A at Year 1:S | 5.6 |
| Serotype 19F at Year 1:S | 5.6 |
| Serotype 21 at Year 1:S | 0.0 |
| Serotype 22F at Year 1:S | 11.1 |
| Serotype 23A at Year 1:S | 5.6 |
| Serotype 38 at Year 1:S | 5.6 |
| Serotype 3 at Year 2:S | 28.6 |
| Serotype 12 at Year 2:S | 0.0 |
| Serotype 15A at Year 2:S | 0.0 |
| Serotype 15B at Year 2:S | 0.0 |
| Serotype 15F at Year 2:S | 0.0 |
| Serotype 19A at Year 2:S | 28.6 |
| Serotype 19F at Year 2:S | 0.0 |
| Serotype 21 at Year 2:S | 0.0 |
| Serotype 22F at Year 2:S | 0.0 |
| Serotype 23A at Year 2:S | 0.0 |
| Serotype 38 at Year 2:S | 0.0 |
| Serotype 3 at Year 3:S | 33.3 |
| Serotype 12 at Year 3:S | 0.0 |
| Serotype 15A at Year 3:S | 0.0 |
| Serotype 15B at Year 3:S | 0.0 |
| Serotype 15F at Year 3:S | 0.0 |
| Serotype 19A at Year 3:S | 0.0 |
| Serotype 19F at Year 3:S | 0.0 |
| Serotype 21 at Year 3:S | 0.0 |
| Serotype 22F at Year 3:S | 0.0 |
| Serotype 23A at Year 3:S | 0.0 |
| Serotype 38 at Year 3:S | 0.0 |
| Serotype 3 at Year 1:I | 0.0 |
| Serotype 12 at Year 1:I | 0.0 |
| Serotype 15A at Year 1:I | 0.0 |
| Serotype 15B at Year 1:I | 0.0 |
| Serotype 15F at Year 1:I | 0.0 |
| Serotype 19A at Year 1:I | 5.6 |
| Serotype 19F at Year 1:I | 0.0 |
| Serotype 21 at Year 1:I | 0.0 |
| Serotype 22F at Year 1:I | 0.0 |
| Serotype 23A at Year 1:I | 0.0 |
| Serotype 38 at Year 1:I | 0.0 |
| Serotype 3 at Year 2:I | 0.0 |
| Serotype 12 at Year 2:I | 0.0 |
| Serotype 15A at Year 2:I | 0.0 |
| Serotype 15B at Year 2:I | 0.0 |
| Serotype 15F at Year 2:I | 0.0 |
| Serotype 19A at Year 2:I | 14.3 |
| Serotype 19F at Year 2:I | 0.0 |
| Serotype 21 at Year 2:I | 0.0 |
| Serotype 22F at Year 2:I | 0.0 |
| Serotype 23A at Year 2:I | 0.0 |
| Serotype 38 at Year 2:I | 0.0 |
| Serotype 3 at Year 3:I | 0.0 |
| Serotype 12 at Year 3:I | 0.0 |
| Serotype 15A at Year 3:I | 0.0 |
| Serotype 15B at Year 3:I | 0.0 |
| Serotype 15F at Year 3:I | 0.0 |
| Serotype 19A at Year 3:I | 0.0 |
| Serotype 19F at Year 3:I | 11.1 |
| Serotype 21 at Year 3:I | 0.0 |
| Serotype 22F at Year 3:I | 0.0 |
| Serotype 23A at Year 3:I | 0.0 |
| Serotype 38 at Year 3:I | 0.0 |
| Serotype 3 at Year 1:R | 0.0 |
| Serotype 12 at Year 1:R | 0.0 |
| Serotype 15A at Year 1:R | 5.6 |
| Serotype 15B at Year 1:R | 0.0 |
| Serotype 15F at Year 1:R | 0.0 |
| Serotype 19A at Year 1:R | 22.2 |
| Serotype 19F at Year 1:R | 0.0 |
| Serotype 21 at Year 1:R | 0.0 |
| Serotype 22F at Year 1:R | 0.0 |
| Serotype 23A at Year 1:R | 0.0 |
| Serotype 38 at Year 1:R | 0.0 |
| Serotype 3 at Year 2:R | 0.0 |
| Serotype 12 at Year 2:R | 0.0 |
| Serotype 15A at Year 2:R | 0.0 |
| Serotype 15B at Year 2:R | 0.0 |
| Serotype 15F at Year 2:R | 0.0 |
| Serotype 19A at Year 2:R | 28.6 |
| Serotype 19F at Year 2:R | 0.0 |
| Serotype 21 at Year 2:R | 0.0 |
| Serotype 22F at Year 2:R | 0.0 |
| Serotype 23A at Year 2:R | 0.0 |
| Serotype 38 at Year 2:R | 0.0 |
| Serotype 3 at Year 3:R | 11.1 |
| Serotype 12 at Year 3:R | 0.0 |
| Serotype 15A at Year 3:R | 0.0 |
| Serotype 15B at Year 3:R | 0.0 |
| Serotype 15F at Year 3:R | 0.0 |
| Serotype 19A at Year 3:R | 11.1 |
| Serotype 19F at Year 3:R | 0.0 |
| Serotype 21 at Year 3:R | 0.0 |
| Serotype 22F at Year 3:R | 0.0 |
| Serotype 23A at Year 3:R | 0.0 |
| Serotype 38 at Year 3:R | 0.0 |
Antimicrobial susceptibility of S pneumoniae isolates for penicillin from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | Mastoid Population |
|---|---|
| Serotype 3 at Year 1:S | 0.0 |
| Serotype 12 at Year 1:S | 5.6 |
| Serotype 15A at Year 1:S | 0.0 |
| Serotype 15B at Year 1:S | 5.6 |
| Serotype 15F at Year 1:S | 0.0 |
| Serotype 19A at Year 1:S | 5.6 |
| Serotype 19F at Year 1:S | 5.6 |
| Serotype 21 at Year 1:S | 0.0 |
| Serotype 22F at Year 1:S | 11.1 |
| Serotype 23A at Year 1:S | 5.6 |
| Serotype 38 at Year 1:S | 5.6 |
| Serotype 3 at Year 2:S | 28.6 |
| Serotype 12 at Year 2:S | 0.0 |
| Serotype 15A at Year 2:S | 0.0 |
| Serotype 15B at Year 2:S | 0.0 |
| Serotype 15F at Year 2:S | 0.0 |
| Serotype 19A at Year 2:S | 14.3 |
| Serotype 19F at Year 2:S | 0.0 |
| Serotype 21 at Year 2:S | 0.0 |
| Serotype 22F at Year 2:S | 0.0 |
| Serotype 23A at Year 2:S | 0.0 |
| Serotype 38 at Year 2:S | 0.0 |
| Serotype 3 at Year 3:S | 44.4 |
| Serotype 12 at Year 3:S | 0.0 |
| Serotype 15A at Year 3:S | 0.0 |
| Serotype 15B at Year 3:S | 0.0 |
| Serotype 15F at Year 3:S | 0.0 |
| Serotype 19A at Year 3:S | 0.0 |
| Serotype 19F at Year 3:S | 0.0 |
| Serotype 21 at Year 3:S | 0.0 |
| Serotype 22F at Year 3:S | 11.1 |
| Serotype 23A at Year 3:S | 0.0 |
| Serotype 38 at Year 3:S | 0.0 |
| Serotype 3 at Year 1:I | 0.0 |
| Serotype 12 at Year 1:I | 0.0 |
| Serotype 15A at Year 1:I | 0.0 |
| Serotype 15B at Year 1:I | 0.0 |
| Serotype 15F at Year 1:I | 0.0 |
| Serotype 19A at Year 1:I | 0.0 |
| Serotype 19F at Year 1:I | 0.0 |
| Serotype 21 at Year 1:I | 0.0 |
| Serotype 22F at Year 1:I | 0.0 |
| Serotype 23A at Year 1:I | 0.0 |
| Serotype 38 at Year 1:I | 0.0 |
| Serotype 3 at Year 2:I | 0.0 |
| Serotype 12 at Year 2:I | 0.0 |
| Serotype 15A at Year 2:I | 0.0 |
| Serotype 15B at Year 2:I | 0.0 |
| Serotype 15F at Year 2:I | 0.0 |
| Serotype 19A at Year 2:I | 0.0 |
| Serotype 19F at Year 2:I | 0.0 |
| Serotype 21 at Year 2:I | 0.0 |
| Serotype 22F at Year 2:I | 0.0 |
| Serotype 23A at Year 2:I | 0.0 |
| Serotype 38 at Year 2:I | 0.0 |
| Serotype 3 at Year 3:I | 0.0 |
| Serotype 12 at Year 3:I | 0.0 |
| Serotype 15A at Year 3:I | 0.0 |
| Serotype 15B at Year 3:I | 0.0 |
| Serotype 15F at Year 3:I | 0.0 |
| Serotype 19A at Year 3:I | 0.0 |
| Serotype 19F at Year 3:I | 0.0 |
| Serotype 21 at Year 3:I | 0.0 |
| Serotype 22F at Year 3:I | 0.0 |
| Serotype 23A at Year 3:I | 0.0 |
| Serotype 38 at Year 3:I | 0.0 |
| Serotype 3 at Year 1:R | 0.0 |
| Serotype 12 at Year 1:R | 0.0 |
| Serotype 15A at Year 1:R | 5.6 |
| Serotype 15B at Year 1:R | 0.0 |
| Serotype 15F at Year 1:R | 0.0 |
| Serotype 19A at Year 1:R | 33.3 |
| Serotype 19F at Year 1:R | 5.6 |
| Serotype 21 at Year 1:R | 0.0 |
| Serotype 22F at Year 1:R | 0.0 |
| Serotype 23A at Year 1:R | 0.0 |
| Serotype 38 at Year 1:R | 0.0 |
| Serotype 3 at Year 2:R | 0.0 |
| Serotype 12 at Year 2:R | 0.0 |
| Serotype 15A at Year 2:R | 0.0 |
| Serotype 15B at Year 2:R | 0.0 |
| Serotype 15F at Year 2:R | 0.0 |
| Serotype 19A at Year 2:R | 57.1 |
| Serotype 19F at Year 2:R | 0.0 |
| Serotype 21 at Year 2:R | 0.0 |
| Serotype 22F at Year 2:R | 0.0 |
| Serotype 23A at Year 2:R | 0.0 |
| Serotype 38 at Year 2:R | 0.0 |
| Serotype 3 at Year 3:R | 0.0 |
| Serotype 12 at Year 3:R | 0.0 |
| Serotype 15A at Year 3:R | 0.0 |
| Serotype 15B at Year 3:R | 0.0 |
| Serotype 15F at Year 3:R | 0.0 |
| Serotype 19A at Year 3:R | 11.1 |
| Serotype 19F at Year 3:R | 11.1 |
| Serotype 21 at Year 3:R | 0.0 |
| Serotype 22F at Year 3:R | 0.0 |
| Serotype 23A at Year 3:R | 0.0 |
| Serotype 38 at Year 3:R | 0.0 |
Antimicrobial susceptibility of S pneumoniae isolates for TMP/S from mastoid samples was categorized as resistant, susceptible or intermediate based on MIC for each serotype at each year of the whole surveillance period. The percentage of S pneumoniae serotypes included 3, 12, 15A, 15B, 15F, 19A, 19F, 21, 22F, 23A, 38, which were to be computed along with exact 2-sided 95% CI based on the observed proportion of isolates. 'Number of isolates analyzed' signifies total number of isolates that were evaluable for this OM.
| percentage of isolates | Mastoid Population |
|---|---|
| Serotype 3 at Year 1:S | 0.0 |
| Serotype 12 at Year 1:S | 0.0 |
| Serotype 15A at Year 1:S | 0.0 |
| Serotype 15B at Year 1:S | 0.0 |
| Serotype 15F at Year 1:S | 0.0 |
| Serotype 19A at Year 1:S | 0.0 |
| Serotype 19F at Year 1:S | 5.6 |
| Serotype 21 at Year 1:S | 0.0 |
| Serotype 22F at Year 1:S | 5.6 |
| Serotype 23A at Year 1:S | 0.0 |
| Serotype 38 at Year 1:S | 0.0 |
| Serotype 3 at Year 2:S | 0.0 |
| Serotype 12 at Year 2:S | 0.0 |
| Serotype 15A at Year 2:S | 0.0 |
| Serotype 15B at Year 2:S | 0.0 |
| Serotype 15F at Year 2:S | 0.0 |
| Serotype 19A at Year 2:S | 0.0 |
| Serotype 19F at Year 2:S | 0.0 |
| Serotype 21 at Year 2:S | 0.0 |
| Serotype 22F at Year 2:S | 0.0 |
| Serotype 23A at Year 2:S | 0.0 |
| Serotype 38 at Year 2:S | 0.0 |
| Serotype 3 at Year 3:S | 33.3 |
| Serotype 12 at Year 3:S | 0.0 |
| Serotype 15A at Year 3:S | 0.0 |
| Serotype 15B at Year 3:S | 0.0 |
| Serotype 15F at Year 3:S | 0.0 |
| Serotype 19A at Year 3:S | 0.0 |
| Serotype 19F at Year 3:S | 0.0 |
| Serotype 21 at Year 3:S | 0.0 |
| Serotype 22F at Year 3:S | 0.0 |
| Serotype 23A at Year 3:S | 0.0 |
| Serotype 38 at Year 3:S | 0.0 |
| Serotype 3 at Year 1:I | 0.0 |
| Serotype 12 at Year 1:I | 0.0 |
| Serotype 15A at Year 1:I | 0.0 |
| Serotype 15B at Year 1:I | 0.0 |
| Serotype 15F at Year 1:I | 0.0 |
| Serotype 19A at Year 1:I | 5.6 |
| Serotype 19F at Year 1:I | 0.0 |
| Serotype 21 at Year 1:I | 0.0 |
| Serotype 22F at Year 1:I | 0.0 |
| Serotype 23A at Year 1:I | 0.0 |
| Serotype 38 at Year 1:I | 0.0 |
| Serotype 3 at Year 2:I | 0.0 |
| Serotype 12 at Year 2:I | 0.0 |
| Serotype 15A at Year 2:I | 0.0 |
| Serotype 15B at Year 2:I | 0.0 |
| Serotype 15F at Year 2:I | 0.0 |
| Serotype 19A at Year 2:I | 28.6 |
| Serotype 19F at Year 2:I | 0.0 |
| Serotype 21 at Year 2:I | 0.0 |
| Serotype 22F at Year 2:I | 0.0 |
| Serotype 23A at Year 2:I | 0.0 |
| Serotype 38 at Year 2:I | 0.0 |
| Serotype 3 at Year 3:I | 0.0 |
| Serotype 12 at Year 3:I | 0.0 |
| Serotype 15A at Year 3:I | 0.0 |
| Serotype 15B at Year 3:I | 0.0 |
| Serotype 15F at Year 3:I | 0.0 |
| Serotype 19A at Year 3:I | 0.0 |
| Serotype 19F at Year 3:I | 11.1 |
| Serotype 21 at Year 3:I | 0.0 |
| Serotype 22F at Year 3:I | 0.0 |
| Serotype 23A at Year 3:I | 0.0 |
| Serotype 38 at Year 3:I | 0.0 |
| Serotype 3 at Year 1:R | 0.0 |
| Serotype 12 at Year 1:R | 5.6 |
| Serotype 15A at Year 1:R | 0.0 |
| Serotype 15B at Year 1:R | 5.6 |
| Serotype 15F at Year 1:R | 0.0 |
| Serotype 19A at Year 1:R | 22.2 |
| Serotype 19F at Year 1:R | 5.6 |
| Serotype 21 at Year 1:R | 0.0 |
| Serotype 22F at Year 1:R | 5.6 |
| Serotype 23A at Year 1:R | 5.6 |
| Serotype 38 at Year 1:R | 5.6 |
| Serotype 3 at Year 2:R | 28.6 |
| Serotype 12 at Year 2:R | 0.0 |
| Serotype 15A at Year 2:R | 0.0 |
| Serotype 15B at Year 2:R | 0.0 |
| Serotype 15F at Year 2:R | 0.0 |
| Serotype 19A at Year 2:R | 42.9 |
| Serotype 19F at Year 2:R | 0.0 |
| Serotype 21 at Year 2:R | 0.0 |
| Serotype 22F at Year 2:R | 0.0 |
| Serotype 23A at Year 2:R | 0.0 |
| Serotype 38 at Year 2:R | 0.0 |
| Serotype 3 at Year 3:R | 11.1 |
| Serotype 12 at Year 3:R | 0.0 |
| Serotype 15A at Year 3:R | 0.0 |
| Serotype 15B at Year 3:R | 0.0 |
| Serotype 15F at Year 3:R | 0.0 |
| Serotype 19A at Year 3:R | 11.1 |
| Serotype 19F at Year 3:R | 0.0 |
| Serotype 21 at Year 3:R | 0.0 |
| Serotype 22F at Year 3:R | 0.0 |
| Serotype 23A at Year 3:R | 0.0 |
| Serotype 38 at Year 3:R | 0.0 |
Percentage of participants with primary diagnosis of otitis media was computed along with exact 2-sided 95% CI based on the observed proportion of participants for each of the 3 surveillance year. Results for baseline period were analyzed for participants who received routinely recommended vaccination of 13vPnC. The cases of otitis media reported during the baseline period were captured by the Texas Children's Hospital, which was the only site that collected this information during the baseline period. Percentage of participants was calculated by dividing number of participants with at least 1 MEF sample for the specified year by total number of participants with at least 1 MEF sample for the 3 year surveillance period.
| percentage of participants | MEF Population |
|---|---|
| Baseline Year 1: 2007 | 24.0 (14.9 to 35.3) |
| Baseline Year 2: 2008 | 45.3 (33.8 to 57.3) |
| Baseline Year 3: 2009 | 30.7 (20.5 to 42.4) |
| Surveillance Year 1: 2011 | 37.8 (32.8 to 43.1) |
| Surveillance Year 2: 2012 | 31.1 (26.3 to 36.2) |
| Surveillance Year 3: 2013 | 31.1 (26.3 to 36.2) |
Percentage of participants with primary diagnosis of mastoiditis was computed along with exact 2-sided 95% CI based on the observed proportion of participants for each of the 3 surveillance year. Percentage of participants was calculated by dividing number of participants with at least 1 mastoid sample for the specified year by total number of participants with at least 1 mastoid sample for the 3 year surveillance period.
| percentage of participants | Mastoid Population |
|---|---|
| Surveillance Year 1 | 52.9 (35.1 to 70.2) |
| Surveillance Year 2 | 20.6 (8.7 to 37.9) |
| Surveillance Year 3 | 26.5 (12.9 to 44.4) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MEF Population | — | — | — |
| Mastoid Population | — | — | — |
All participants from whom microbiologic specimen of S pneumoniae isolates from MEF or mastoiditis sample were obtained during surveillance period.
| Age, Continuous(months) | MEF Population | Mastoid Population | Total |
|---|---|---|---|
| Mean | 28.7 ± 26.0 | 35.5 ± 47.2 | 29.3 ± 28.5 |
| Sex/Gender, Customized(Participants) | MEF Population | Mastoid Population | Total |
|---|---|---|---|
| Female | 144 | 18 | 162 |
| Male | 209 | 16 | 225 |
| Not collected | 4 | 0 | 4 |
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from May 2010 to primary completion in Dec 2013, 42 months.
Results were first posted in Nov 2020, 6 years 10 months after primary completion.
Of 22 observational studies under Otitis Media, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 67. This study's 42 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.